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figure 1 
a) A three-dimensional model of chick cerebellum mitochondrion. The outer membrane is displayed in 
translucent dark blue and the cristae in yellow. 
b) A three-dimensional model of the tomogram in  with the outer and inner boundary 
membranes shown in dark blue and light blue respectively. Four different cristae 
are displayed in red, yellow, green and grey along with two segments of 
endoplasmic reticulum in green and light brown. The outer membrane 
and the inner boundary membrane are rendered translucent so that 
the cristal membranes can be viewed through it. The inner boundary 
membrane and the cristal membrane are components of the inner 
mitochondrial membrane and are one continuous surface joined 
at 30 nm diameter tubular connections or crista junctions. 
[5 and http://www.sci.sdsu.edu/TFrey/MitoMovies/CrisMitoERMovie.htm]
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1 Mitochondria
Structure
Mitochondria are characterized by a double system of membranes delimitating 
four “mitochondrial spaces” where different metabolic pathways take place: 
the outer membrane, the inner membrane, the intermembrane space and the 
matrix. 
The outer mitochondrial membrane (OMM) is permeable to ions and small 
proteins (MW<10 kDa) because of the abundance of a large conductance 
channel, known as mitochondrial porin or voltage-dependent anion channel 
(VDAC) [1]. Hence the intermembrane space composition is very similar to 
the cytoplasmic one in terms of metabolites and ions concentrations. Other 
proteins active in the OMM are involved in import of both proteins synthesized 
in the cytosol and activated fatty acids into the matrix.
The intermembrane space contains about 6% of total mitochondrial protein and 
the most abundant member is represented by cytochrome c, a component of 
the oxidative phosphorylation (oxphos) system. Also pro-apoptotic proteins 
as well as enzymes, which are involved in the energetic metabolism (adenylate 
kinase and creatine kinase), in reactive oxygen species removal and in the 
membrane organization, are localized in the intermembrane space.
Respect to the OMM the inner mitochondrial membrane (IMM) has a higher 
ratio protein: phospholipids (3:1 vs 1:1 in the OMM) and it is rich in cardiolipin 
that seems to play a pivotal role not only in the maintenance of membrane 
structure but also in the interaction between transmembrane proteins [2,3]. 
The inner membrane is organized in numerous invaginations, called cristae, 
protruding into the matrix. Mitochondrial cristae contain all complexes forming 
the oxphos system and since oxphos is the major source of cellular ATP 
cristae extension and organization are dependent on energetic demand of cell. 
According to their different metabolic requirements, muscle cells mitochondria 
usually contain more cristae than liver cells mitochondria indicating a greater 
figure 2
Mitochondrion: schematic 
representation
figure 3 
Mitochondrion: electron micrograph of 
sectional view
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content in the oxidative phosphorylation 
complexes [4]. Besides oxphos 
complexes IMM contains several ion 
channels, proteins involved in the 
import of nuclear-encoded proteins and 
the ADP/ATP exchanger that allows to 
mitochondrial-synthesized ATP to reach 
the cytosol. 
The IMM is actually organized in two 
distinct domains: the inner boundary 
membrane, facing the OMM and 
delimitating the intermembrane space, 
and the cristae membrane protruding 
into the matrix. 
The application of electron microscopy 
tomography (EMT) has provided very 
realistic model of the internal structure of mitochondria. This technique is 
based on collecting and merging several views from a relative thick specimen 
allowing the generation of reliable 3D renders. EMT analyses of a variety of 
mitochondria, isolated and in situ, have provided overwhelming evidence 
that cristae are not simply random folds in the inner membrane but rather 
internal compartments formed by invagination of the membrane [5,6]. These 
invaginations originate at narrow sites where the inner boundary membrane and 
the cristae membrane form tubular connection. The width of these dynamic 
structures, called cristae junctions, might determine the existence of a fifth 
“mitochondrial space”: the intracristae space [4]. The application of EMT to 
mitochondria study has showed the high variability of cristae morphology, not 
only among different organism but also within a single organelle [fig.1].
Finally, contact sites are defined as tight connection regions between OMM 
and IMM: in these regions the two membranes interact to allow the import of 
nuclear-encoded proteins or the export of newly synthesized ATP.
Mitochondrial matrix contains a very highly concentrated mixture of several 
proteins; this is the site of fatty acids β-oxidation and Krebs cycle. Along with 
enzymes and cofactors of catabolic metabolism, the matrix contains also all 
the components of mitochondrial protein synthesis machinery and several 
copies of mitochondrial DNA molecules as well as antioxidant enzymes like 
manganese superoxide dismutase, catalase, glutathione peroxidase and 
peroxiredoxin.
Mitochondria are usually represented as rounded individual organelles but 
it is now well known that 
images obtained by electron 
microscopy analysis 
[fig. 2 and fig. 3] have 
been actually interpreted 
incorrectly. The development 
of fluorescence microscopy 
along with mitochondrial 
fluorescence probes has 
allowed to obtain a more 
accurate and realistic view of 
mitochondrial organization 
in living cells. As shown in 
figure 4 
Mitochondrial network imaged by 
fluorecence microscopy
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fig. 4 mitochondria appear more like a continuous tubular network rather than 
single entities and it is now clear that electron microscopy images are actually 
transversal section view of a single mitochondrial tubule [4]. The relevance and 
dynamic of mitochondrial network organization will be discussed in Fission & 
Fusion paragraph.
Genome
According to the evolution theory, mitochondria derives from an 
ancestral symbiotic relationship between an aerobic bacteria 
and a primordial eukaryotic cell. After the symbiotic event, 
part of the proto-mitochondrion genome, initially providing all 
the information needed by a free-living organism, has been 
transferred to the nucleus [7]. 
Even if mitochondria in the lower and higher eukaryotes have 
preserved quite the same type of information in their own DNA, they are 
still completely dependent on the nuclear genome in terms of catabolic and 
energetic metabolism, protein translation and DNA replication [8].
In mammalian mitochondrial DNA (mtDNA) is a double-stranded circular 
molecule formed by 16568 base pairs with very peculiar structural and 
functional characteristics. The two strands are referred to as heavy (H) and 
light (L), reflecting their behavior in density gradients. Unlike the nuclear 
DNA (nDNA) mitochondrial genome is highly compact: there are no introns 
or spacers between genes that actually may in some case overlap. More 
there is only one non-coding region of approximately 1 Kb that contains the 
replication origin for leading strand synthesis (OH) and the promoters for 
transcription of the H- and L-strands.
Since the formation of fungal-animal lineage mitochondrial genetic code began 
to drift so that mitochondrial genes cannot longer be interpreted by the nuclear 
system. For this reason, since then, the mtDNA set has remained relatively 
constant through the evolution [8]. 
In Mammalian mtDNA molecule retains only 37 genes: the 12S and 16S rRNA 
and the 22 tRNAs representing the mitochondrial translational machinery 
along with 13 structural genes [fig. 5]. Gene transcription occurs symmetrically 
starting from two promoters, one for the G-rich heavy strand (PH) the other for 
the C-rich light strand (PL), and it progresses around the entire molecule. The 
polycistronic message is then processed to give the final product: the tRNA 
genes, which are interspersed between many of the protein-coding genes, are 
cleaved out, then mRNAs are polyadenylated [8].
The 13 mtDNA-encoded proteins are structural subunits of oxidative 
phosphorylation system. They include: seven (ND1-ND4, ND4L, ND5, ND6) 
of the 46 peptides of Complex I, one (cytochrome b) of the eleven peptides of 
Complex III, three (COI, COII, COIII) of the 13 peptides of Complex IV and two 
(ATP6, ATP8) of the 16 peptides of Complex V. 
nDNA encodes all other mitochondrial proteins including all four subunits 
of Complex II, the mitochondrial DNA polymerase γ subunits (POLG), the 
mitochondrial RNA polymerase components, mitochondrial transcription and 
translation factors and the other mitochondrial metabolic enzymes [8].
The high mutational rate that distinguishes mtDNA from nDNA is the probable 
reason for the poor residual genetic content in mtDNA, while the maintenance 
of some oxphos gene in mitochondrial genome might be justified by the 
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figure 5
Human mitochondrial DNA map. Capital letters indicate tRNA genes.
introduction
Mitochondria
7
necessity of a tight connection between nucleus and mitochondria in order to 
match mitochondrial function with cell requirements.
Each somatic cell contains several copies of mtDNA, in the range of 103-104. 
mtDNA is organized in association with proteins in a structure called nucleoid at 
approximately 2–10 copies per nucleoid [9]. In higher eukaryotes mitochondrial 
nucleoid is reported to contain TFAM, a mitochondrial transcription factor, 
SSBP1 (single-stranded binding protein1), Twinkle (a helicase), and LON 
protease [10,11]. The nucleoids-associated proteins are supposed to be involved 
not only in processing but also in the maintenance of mtDNA. Lon is an ATP-
dependent protease whose substrates are represented by oxidatively modified 
and unfolded peptides [12]. Interestingly, this protease shows the capability 
to specifically bind mtDNA and has been shown to co-immunoprecipitate 
with polymerase γ and Twinkle [12]. Since substrate binding facilitates ATP 
hydrolysis and proteolysis while inhibiting DNA binding, Lon has the potential 
to be a regulator of mitochondrial homeostasis - controlling both proteins and 
mtDNA - by acting as a sensor of the mitochondrial environment[13]. 
Mitochondrial genome duplicates independently from cell cycle in mitotic as 
well as in post mitotic cells. Individual mtDNA molecules can duplicate more 
than once or not at all in a single cell cycle [14] and at cell division they are 
distributed randomly into the daughter cells, according to the mechanism 
known as Random Segregation. 
Since each cell is provided with multiple copies of mtDNA molecules, the 
presence of a mutation can result in two different genetic conditions defined 
as Homoplasmy and Heteroplasmy. We refer to homoplasmy when all 
mtDNA molecules in a cell or in an individual are identical, i.e. all mutated or 
all wild type. On the other hand, in the heteroplasmic status mutated and wild-
type molecules coexist in the same cell or in the same individual. If this is the 
case, because of the random segregation, at each cell division the proportion 
of mutant and wild type mtDNA can potentially drift toward homoplasmic 
mutant or homoplasmic wild type state. The notion of heteroplasmy can be 
figure 6
Diagrammatic representation of changes in the number of mitochondria during development of the female germ line. An estimate of the number 
of mitochondria is indicated at each stage of germ line development. A genetic bottleneck for the transmission of mtDNA occurs in the primordial 
germ cells. Development to the mature oocyte involves at least a 10,000 fold increase in the number of mitochondria. [9]
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extended at the entire organism where only few tissues may be characterized 
by the presence of a mtDNA mutation. As general rule silent mtDNA mutations 
exist in the homoplasmic status while heteroplasmy is the typical condition of 
pathogenic mutations. 
mtDNA is exclusively transmitted from the maternal lineage through the egg 
cytoplasm. In the zygote the paternal mtDNA is indeed eliminated from the 
fertilized egg probably because along their way to the oocyte sperm cells 
are subjected to a high risk of oxidative damage. Despite the high number 
of mtDNA copies in mature oocytes (105), only a few of them are transmitted 
during meiosis because of the phenomenon known as bottleneck [14]. In the 
fig. 6 are represented the changes in the number of mitochondria during the 
development of the female germ line: the mitochondrial bottleneck occurs in 
the primordial germ line while a massive increase in cellular mtDNA copies 
number occurs during the formation of mature oocyte. During one or both of 
these steps, in presence of mtDNA mutations, the genomic variants could 
be “selected” causing the genetic shift between generations, likewise the 
mitochondrial random segregation during the mitosis can cause a genetic shift 
during the life of a mtDNA mutation carrier. 
This pattern could be further complicated by the possibility that not all mtDNA 
mutations are equally treated in the germ line or during duplication, which 
means that some mutations could actually have a replicative advantage. 
Different studies have focused on this issue with different results depending 
on the mutation considered, but so far the more probable hypothesis is that, in 
mammals, the transmission of polymorphic and pathogenic mtDNA sequence 
variants is primarily a stochastic process [9].
Oxphos
Mitochondria, performing the last steps of cellular catabolism, are the primary 
source of energy for the cell. Reduced equivalents deriving from oxidation 
of carbohydrates, proteins or lipids are indeed utilized by these organelles 
to produce adenosin triphosphate (ATP) the major energetic molecule in the 
cell. Pyruvate, aminoacids and fatty acids deriving from cytosolic catabolic 
pathways are further oxidized in mitochondria matrix through Krebs cycle or 
β-oxidation to produce NADH (nicotinamide adenine dinucleotide, reduced 
form) and FADH2 (flavine adenine dinucleotide, reduced form), as substrates 
introduction
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of the respiratory chain. 
Since the inner membrane is freely permeable only to O2, CO2 and H2O2 
and it lacks of NADH transporters, electrons deriving from cytosolic NADH 
are transferred into mitochondrial matrix through shuttle systems. Cytosolic 
oxaloacetate is reduced to malate that can cross the inner membrane, once in 
the matrix malate is reoxidized to oxaloacetate. The reaction is catalyzed by 
malate dehydrogenase and involves NAD reduction. 
Respiratory chain, also called electron transport chain (ETC), consists of 
four multi-protein enzymatic complexes embedded in the inner mitochondrial 
membrane and two mobile electron carriers, coenzyme Q (CoQ), also called 
ubiquinone, and cytochrome c. 
ETC complexes transfer electrons deriving from NADH and FADH2 to molecular 
oxygen producing  water. The oxygen reduction occurs through a multi-steps 
process: Complex I (NADH:Ubiquinone oxidoreductase) or Complex II 
(Succinate:Ubiquinone oxidoreductase) sequentially transfer two electrons 
deriving from NADH or FADH2  to CoQ giving ubisemiquinone (CoQ•)  and 
then ubiquinol (CoQH2). 
Complex II is the only enzyme of respiratory chain that does not show proton-
pumping activity but it represents an alternative entry point for electrons 
and a checkpoint for the coordination between Krebs cycle and oxidative 
phosphorylation. Complex II [see references in 15 and 16] is composed of four subunits 
all encoded by nuclear genes: the two largest subunits lie in the matrix space 
and contain a covalently bound flavine adenine dinucleotide together with 
three Fe-S clusters. Because of its low midpoint potential the 4Fe-4S cluster 
is supposed not to be part of the electron transfer pathway but rather might 
represent a structural or regulatory moiety of the enzyme [16]. The other two 
subunits, less conserved, are localized in the membrane and contain a type 
b heme and two ubiquinone/ubiquinol binding domains localized on opposite 
sites of the inner membrane. The large distance between the two quinones 
would suggest that only the quinone bound near the cytplasmic side of inner 
membrane is part of the electron transfer chain. The catalytic mechanism 
consists in the reduction of FAD by the succinate molecule followed by electron 
transfer to CoQ through the Fe-S clusters chain. The role of heme b is not yet 
clearly understood. Besides its potential structural role, this prosthetic group 
could take part to redox reactions only during reverse electron transfer, being 
capable to participate in fumarate reduction but not in succinate oxidation [17]. 
Ubiquinol is oxidized by Complex III (Ubiquinol:Cytochrome c oxidoreductase) 
which reduces cytochrome c. Complex III [see references in15 and 18]  exists as symmetric 
dimer where each monomer consists of eleven subunits. The catalytic core 
is formed by three subunits containing all the redox centers of the enzyme: 
cytochrome b, cytochrome c1 and an iron-sulfur protein known as Rieske 
protein. Cytochrome b contains two heme groups – b565 and b560 – and two 
ubiquinone/ubiquinol binding sites called P center and N center; cytochrome 
c1 is the cytochrome c electron donor. The redox proteins along with other 
three subunits (7, 10, 11) span the inner membrane while the remaining 
subunits are exposed to the matrix or to the intermembrane space. The 
catalytic mechanism is characterized by oxidation of ubiquinol and reduction 
of ubiquinone during the Q-Cycle. This process allows the translocation of 
four protons across the membrane and it occurs through one-electron steps 
oxidation of ubiquinol. Briefly, one electron deriving from the ubiquinol on the P 
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center sequentially flows from the high-potential Fe2-S2 cluster to cytochrome 
c1 and cytochrome c. The ubiquinol oxidation is completed through a different 
pathway: the second electron reduces heme b560, heme b565 and finally a 
molecule of ubiquinone bound at the N center to its ubisemiquinone form. The 
cycle ends with the binding of a second CoQH2 at the P center: in this case, 
the first electron is used to reduce a second cytochrome c molecule while the 
other flows through heme b565 and b560 to reduce the ubisemiquinone at the N 
center determining the uptake of two protons from the matrix. The complete 
reaction can be so represented: 
QH2 + 2 cyt cox + 2H
+
matrix  → Q + 2 cyt cred + 4H
+
intermembrane space.
From cytochrome c electrons flow to Complex IV (Cytochrome c oxidase) 
that finally reduces molecular oxygen to water. Complex IV [see references in 15, 19] 
is composed of thirteen subunits; three of them - I, II and III - are encoded 
by mitochondrial genes and represent the catalytic core of the enzyme. In 
subunit I are localized a copper atom - CuB - and two heme groups, called 
a and a3. Subunit II contains CuA, a binuclear copper center. The catalytic 
action occurs through  Cytochrome c oxidation by CuA. Heme a represents the 
bridge between CuA and the heme-copper center formed by CuB and heme a3 
where molecular oxygen is bound and reduced to water. Nevertheless subunit 
III is well conserved during evolution, its function still remains uncertain: 
the absence of redox centers excludes its participation to electron transfer. 
Moreover, studies in P. denitrificans have showed that a cytochrome oxidase 
lacking of subunit III conserves the capacity of translocate protons suggesting 
that this subunit is not determinant for proton pumping [20]. 
The oxygen reduction by Complex IV occurs through a multi-steps mechanism 
in which different iron-oxygen intermediates are formed thanks to the 
cooperation between heme a3 and CuB. The electron transfer is coupled with 
the uptake of an equal number of protons from the matrix so that for each 
complete cycle four protons are vectorially translocated into the intermembrane 
space. The complex is provided with three potential channels by which proton 
transport can be accomplished. The so-called K channel allows the access of 
the four protons to the binuclear site for water formation, whereas D and H 
channels span the entire membrane layer. These channels are characterized 
by amino acids with protonable side chain, capable to form hydrogen bonds 
with nearby amino acids and to create a bridge between the matrix and the 
intermembrane space. However, site-directed mutagenesis studies, performed 
with the bacterial enzyme, suggest that the H channel is not involved in proton 
translocation[21]. The nuclear-encoded subunits exposed ether to the matrix 
or to the intermembrane space, are not directly involved in the catalytic 
mechanism and are supposed to have a regulatory function.
The energy released by the esorgonic electron transfer to the oxygen is then 
converted in what P. Mitchell, who first proposed the chemiosmotic theory, 
called protonmotive force. Contextually to the redox reactions Complex I, III 
and IV pump protons from the matrix into the intermembrane space so that 
through the inner membrane is established an electrochemical gradient (ΔP) 
consisting of two components: ΔΨ (electric) and ΔpH  (chemical). 
Complex V (ATP synthase) converts the energy stored in ΔP in high-energy 
phosphate bonds readily available for cell demand. Complex V [see references in 15 
and  22] F0 sector, embedded in the inner membrane, contains a channel that 
figure 7
Schematic representation of oxphos system.
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allows to protons to flow back to the matrix thanks to the electrochemical 
gradient. The energy released by ΔP dissipation is linked to ATP synthesis by 
the Complex V soluble portion, F1, through a tree steps mechanism in which 
ADP and Pi are bound and condensed to form ATP that is finally released 
into the matrix. The mammalian F0 component contains nine subunits (a, b, 
cn, d, e, f, g, A6L, F6), while the F1 hydrophilic component has a α3, β3, γ, δ, ε 
composition where β subunits represent the active sites for the ATP synthesis. 
In the inner membrane 9-12 c subunits are arranged in a ring connected by 
a stalk to the catalytic component in the hydrophilic portion. The γ, δ and ε 
subunits compose the central part of the stalk moiety, while the peripheral 
stalk, lying to one side of the complex is composed of b, d, F6 and OSCP 
(oligomycin sensitivity conferring protein) subunits.
Complex V works as a rotary motor in which the protons flow through the 
F0 portion modulates the properties of the β subunits. The catalytic subunits 
exist in three different conformations associated with different affinity for ADP-
Pi and ATP, according to the binding-change mechanism proposed by Boyer 
[23]. The energy deriving from proton gradient dissipation is actually needed 
to eliminate the strong interaction between the newly synthesized ATP and 
the catalytic site. The transition between the three different β conformations 
is driven by the rotation of γ subunit. The b subunit along with other stalk 
components works as a tether between the F0 and the α3-β3 module inducing 
the distortion of the β subunits in response to the rotor (c-ring, γ, δ, ε) motion. 
The proton channel is supposed to be localized in the interface between a and 
c subunits and the translocation is likely achieved by amino acids provided 
with carboxylate groups whose elecrostatic interactions drive the rotor.
The IF1 (F1 inhibitor) protein, active as dimer, is capable to bind F1 stabilizing the 
ATP synthase dimeric structure, which has been shown to have a determinant 
role in the cristae organization. Furthermore, IF1 is active at pH values < 6.5 
so that it can works as pH sensor inhibiting the ATP synthase activity in acidic 
conditions, i.e. when the proton gradient collapses [22]. 
Thus, the ETC and ATP synthase work together to complete the oxidation of 
energetic nutrients and produce energy through the oxidative phosphorylation 
pathway [fig. 7]. 
ATP is transported out of mitochondria by ANT (adenine nucleotide translocator) 
a dimeric transporter located in the inner mitochondrial membrane. ANT 
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exchanges cytosolic ADP for mitochondrial ATP, the electrogenic antiport 
being driven by the membrane electrical potential difference. The Pi required 
in the matrix for the synthesis of ATP is as well imported from the cytosol by a 
Pi-H
+ symport system [24]. The electrochemical gradient formed by ETC trough 
the inner mitochondrial membrane thus not only provides the thermodynamic 
force to drive the synthesis and the release of ATP in the matrix but also drives 
the import of Complex V substrates (ADP and Pi) from cytosol. 
ETC activity is thus tightly coupled to Complex V activity by transmembrane 
potential so that mitochondrial oxygen consumption rate is indirectly regulated 
by both matrix ADP concentration and Complex V activity. In absence of ADP, 
oxygen consumption rate is regulated by proton leakage across the inner 
membrane, then, in physiological condition, it is very slow. We refer to this 
condition as state 4 of respiration. When ADP is available for Complex V 
protons start to flow through F0 and the inner membrane becomes depolarized. 
The depolarization has to be counteracted by ETC that reduces oxygen at a 
higher rate to restore membrane potential determining the so-called state 3 of 
respiration. The presence of uncoupling drugs such as DNP (2,4-dinitrophenol) 
or proteins as UCP1, 2 or 3 (uncoupling protein) makes the inner membrane 
permeable to protons, preventing the possibility to maintain the potential. In 
this condition ETC works at its maximum rate causing a sharp increase in 
oxygen consumption and determining the so-called uncoupled respiration.
The coupling between ETC and Complex V and then the correct control of 
mitochondrial membrane potential is very important to preserve mitochondria 
functions; ΔP is in fact required not only for ATP synthesis but also to drive 
the import of substrates and proteins encoded in the cytoplasm and for ions 
homeostasis: the electrical component of membrane potential (-180 mV) 
drives the import of Ca2+ into the matrix through a uniporter, while Ca2+ efflux 
is accomplished by Na+/Ca2+ and H+/Ca2+ exchangers [1]. Since several cellular 
functions, like muscular contraction, neuronal secretion, hormone secretion 
and apoptosis are controlled by oscillations of cytosolic Ca2+ concentration 
is clear that mitochondrial buffering function need to be strictly preserved to 
maintain the whole cellular physiology.
For long time oxphos complexes have been supposed to freely diffuse in the 
inner membrane, with the electron transfer being based on random collision 
between respiratory chain components. Currently, thank to either kinetic or 
proteomic studies, the random collision model also defined as “fluid state 
model” has been substituted with an integrated model where single oxphos 
complexes would coexist with supercomplexes formed by interaction of 
Complex I, III and IV organized, in variable stoichiometries, in the so-called 
respirosome. The supramolecular organization of oxphos complexes has 
been reported in a wide range of organisms, from bacteria to fungi, yeasts, 
plants and higher eukaryotes [25]. The functional relevance of the respirosome 
is suggested by the dependence of Complex I, in terms of assembly and 
stability, on its interaction with Complex III. Cells harboring a mutation in 
cytochrome c gene leading to impairment in Complex III assembling showed 
in fact a concomitant reduction of Complex I amount [26]. The same results 
have been obtained in mitochondria isolated from human skeletal muscle 
[27] providing evidence that the formation of supercomplexes is essential for 
Complex I assembly/stability. 
Characterization by transmission electron microscopy of bovine heart 
supercomplexes has confirmed the I1III2 and I1III2IV1 stoichiometry previously 
deduced from BN-PAGE (Blue Native Polyacrylamide Gel Electrophoresis) 
O2 O2•
-
e- e- e-
H2O2 OH•
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data [28, 29].  Since after isolation I1III2IV1 remains intact and active, whereas a 
minor fraction of I1III2 disintegrate into its individual complexes, Complex IV 
might play an important role in the stability of the respirosome [29]. According to 
the integrate model, in physiological conditions individual oxphos complexes 
exist in equilibrium with supercomplexes so that, depending on metabolic 
conditions electron transfer in the ETC would occur via substrate channeling 
of ubiquinone and cytochrome c due to supercomplex formation or via random 
diffusion of these small carriers [30]. One major determinant in oxphos complexes 
interaction is represented by lipids in the membrane layer. Cardiolipin plays a 
pivotal role in the assembly and stabilization of functional supercomplexes [31] 
but other than participating in the association between individual complexes, 
membrane lipids could be also important in providing the correct environment 
for CoQ function [25]. The advantage of being organized in supercomplexes 
could derive primary from substrate channeling: the close proximity of enzymes 
catalyzing consecutive reactions of the same pathway would in fact increased 
the metabolic flow resulting in an increased efficiency of the entire system; 
however, a role of supercomplexes in preventing electrons escaping and then 
ROS production cannot be excluded [25].  
It has been in fact estimated that a low proportion (~0.2%) of the oxygen utilized 
by mitochondria is converted by partial reduction to reactive oxygen species, 
a natural by-product of ETC [4]. It is now well known that, at low concentrations, 
ROS play a role in several signaling pathways through reversible modification 
of highly conserved cysteines or metionine in several proteins [32], but ROS 
accumulation due to increased production or inefficient removal may have 
deleterious consequences for the cell. 
Reactive Oxygen Species
Reactive oxygen species (ROS) are a variety of molecules and free radicals 
- chemical species with one unpaired electron - deriving from partial reduction 
of molecular oxygen. The reduction of molecular oxygen by one electron at time 
produces intermediates with different stability and growing oxidative power:
Superoxide anion (O2•-), the product of a one-electron reduction of oxygen, 
can dismutate, spontaneously or trough reaction catalyzed by superoxide 
dismutases, to hydrogen peroxide. This species is not highly oxidant per se but 
can react with nitric oxide (NO•) in a reaction controlled by the rate of diffusion 
of both radicals to give peroxynitrite (ONOO ) a more powerful oxidant. 
Hydrogen peroxide (H2O2) is a non-radical relatively stable molecule that may 
work as messenger in signal transduction pathways integrating mitochondrial 
function with the rest of the cell.
Reduction of hydrogen peroxide by means of a ferrous anion produces 
hydroxyl (OH•), one of the strongest oxidants in nature; the presence of O2•- 
may propagate this process cycling reducing the transition metal. 
Mitochondria are an important source of ROS: ETC works basically with one-
electron transfer steps and the redox centers present in oxphos complexes 
can potentially transfer electrons to molecular oxygen. ROS production in 
mitochondria depends mainly on both oxygen concentration and redox status 
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of ETC complexes, and in physiological conditions both parameters are 
actually determined by tissue metabolic requirements. Complex I and III are 
the main source of superoxide anion in mitochondria. 
The poor knowledge of Complex I structure has not permitted to precisely 
locate the site of electron leak and all major cofactors have been proposed 
as site of oxygen reduction: FMN [33], iron-sulfur clusters N2 [34] and N1a [35] 
and the semiquinone radical formed upon ubiquinone reduction [36]. However, 
the electron leak from one or more of these sites results in superoxide anion 
radicals  (O2•-) production in the matrix 
[37].
One-electron reduction of oxygen in Complex III is accomplished by 
ubisemiquinone and increases in presence of antimycin, an inhibitor that binds 
one of the CoQ reduction sites; the release of superoxide anion from Complex 
III may occur on both side of inner membrane [37]. 
Anion superoxide production by Complex I reaches its maximal rate during 
reverse electron transfer (RET). RET occurs when electron supply, i.e. from 
succinate, reduces CoQ that in presence of a significant high ΔP could give 
electrons back to Complex I leading to formation of NADH from NAD+ through 
FMN; the role of Complex I in this process has been confirmed by use of 
rotenone. The RET-associated superoxide production is deeply dependent on 
ΔP since it could be completely abolished by even small decreases in the proton 
electrochemical potential achieved through addition of ADP or uncoupler [38]. 
Moreover, it has been shown to be more sensitive to changes in the ΔpH, than 
in the ΔΨ component [39]. Increase in Complex I prosthetic groups reduction 
may also occurs in presence of increased NADH/NAD+ ratio that may arise 
when respiratory chain activity is inhibited. Thus, it is clear that alterations 
either in Complex I activity and structure or in the whole oxphos system might 
likely lead to an overproduction of ROS that could reflect in a non-reversible 
oxidative modification of lipids, proteins and nucleic acids. Although it has 
been demonstrated that inhibition threshold for Complex I (30%) or Complex 
III (70%) must be reached before to observe a significant ROS production[40], 
in a context of partial energetic impairment due to mutations in mtDNA genome 
also minimal shifts in the redox equilibrium might represent a further input of 
stress for the cell.
Indeed, every molecule in the cell can be a target of ROS action: membrane 
lipids are particular vulnerable due to the presence of double-bounds, proteins 
may be oxidized by ROS at thiol groups of cysteine or metionine while 
tyrosine residues may undergo nitrosilation by nitric reactive species whose 
metabolism is linked to that of ROS. Besides being the major source of ROS, 
mitochondria are also highly sensitive to oxidative damage: the presence of 
metals in the prosthetic groups of ETC complexes makes oxphos system an 
easy target of hydrogen peroxide. 
An interesting issue is provided by the “mitochondrial theory of aging” where 
mtDNA is supposed to play a pivotal role in the aging process [41]. Probably 
for a minor efficiency in their repair system machinery mitochondrial DNA 
molecules seem in fact to be particularly prone to oxidative damage. mtDNA 
oxidative modification will lead to altered or reduced protein synthesis and so 
to incompetent mitochondrial metabolism through a vicious cycle leading in 
turn to energy deprivation, redox imbalance and cell dysfunction. According to 
this, there are evidences that hallmarks of ROS-mediated nucleotide damage, 
such as 8-hydroxy-deoxyguanosine, are more prevalent in aged tissues [42]. 
The mitochondrial aging theory is also supported by several reports showing 
the accumulation of oxidative modified proteins in neurodegenerative 
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pathologies, very common among old people, such as Parkinson’s disease [43] 
or Alzheimer’s disease [44].
Because of the potential deleterious effect of a natural by-product of 
mitochondrial metabolism aerobic cells evolved efficient systems for ROS 
scavenging. The ROS-scavenging system must be highly regulated to rapidly 
answer to even slight changes in the redox state of cell. Since all genes implied 
in maintaining the correct balance between ROS production and scavenging 
are nuclear encoded, a proper mitochondria-nucleus cross-talk is of primary 
importance to counteract oxidative stress risk.
Superoxide dismutase catalyzes dismutation of superoxide anion in hydrogen 
peroxide. In mammalian three genes encoding superoxide dismutases 
with different localization have been found [45]. SOD1 and SOD3 encode 
two enzymes containing copper and zinc in their catalytic site (CuZnSOD) 
but showing different localization: SOD1 product is localized in cytoplasm, 
nuclear compartments, mitochondrial intermembrane space and lysosomes of 
mammalian cells while SOD3 product exists as a homotetramer and is located 
in the extracellular environment. The expression pattern of SOD3 is highly 
restricted to specific cell type and tissues where its activity can exceed that 
of SOD1 and SOD2. A third isoform of SODs has manganese as a cofactor 
(MnSOD) and is localized in mitochondrial matrix of aerobic cells where it is 
active in the tetrameric form [45].
Glutathione peroxidase (GPX) contains selenium in the catalytic site and 
catalyzes reduction of hydrogen peroxide by glutathione; different isoforms 
are present in cytoplasm and mitochondria and are differently expressed 
depending on tissues [11]. 
Peroxiredoxins (Prdx) are thiol-dependent enzymes working as hydrogen 
peroxide scavenger; isoform 3 is exclusively localized in mitochondrial matrix 
[46].
Catalase catalyzes hydrogen peroxide conversion in H2O and O2, is a tetramer 
containing heme as prosthetic group and is localized in peroxisomes, in cytosol 
and in heart mitochondria [4]. 
Non-enzymatic systems like glutathione, thioredoxines and vitamins (E, C) 
which can participate to catalytic action of antioxidant enzymes as cofactors, 
are as well fundamental in maintaining the balance in the redox state of 
cells.
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Mitochondrial Pathologies
Mitochondrial pathologies are a heterogeneous group of clinical manifestations 
characterized by oxidative phosphorylation impairment. At the beginning of 
their recognition mitochondrial pathologies were regarded as rare disorders 
but indeed they are more frequent than originally thought. A correct estimation 
of the incidence of these disorders seem to be not so straightforward probably 
because of the great variability of age of onset, but they are usually referred 
as the most frequent pathologies among the inborn errors metabolism group 
[47].
Mitochondrial diseases manifest usually as multisystem syndromes in 
which tissues or organs most commonly involved are those characterized 
by high-energy demand (skeletal muscle, nervous system and heart) so 
that encephalo-myopathies or encephalo-cardio-myopathies are classic 
phenotypes. However, also other tissues can be affected and cases of single 
tissue involvement are not rare. The onset and the course of mitochondrial 
pathologies can vary greatly, ranging from early to late-onset, slowly or rapidly 
progressive. The outcome can be lethal in the childhood or highly disabling. 
Because of the unique mitochondria peculiarities mitochondrial pathologies 
can arise from different kind of genetic alterations: since these organelles are 
deeply dependent on nDNA nevertheless they preserve part of their own DNA, 
mitochondrial disorders can be caused by mutations in both genomes.  
mtDNA mutations
The first evidence of a pathology linked to a mutation in mtDNA dates back to 
1988 when Wallace and coworkers found a point mutation in the gene encoding 
subunit 4 of Complex I in a family with Leber’s hereditary optic neuropathy 
(LHON) [48]. So far more than hundred mtDNA mutations have been associated 
to several disorders and the list seem to be not still complete[49].
Pathogenic mtDNA point mutations have been mapped along all mitochondrial 
genome and may occur in structural genes as well as in rRNA or tRNA genes; 
pathologies caused by these mutations are maternally transmitted. Conversely, 
sporadic pathologies have been associated to mtDNA rearrangements that 
usually occur spontaneously: the most common deletion is found in one third 
of patients and involves a 5 Kbp segment [14] fig. 8 morbidity map. Unlike 
point mutations affecting structural genes, mtDNA deletions determine lack of 
several gene functions; a similar effect is caused by rRNA and tRNA genes 
point mutations that lead to a general impairment of mitochondrial protein 
translation machinery affecting most of the oxphos complexes.
Since mtDNA contains only 13 structural genes - all encoding subunits of 
oxphos system - and RNA genes required for synthesis of those proteins, 
pathologies caused by mtDNA genetic defects share the common characteristic 
of a deficient oxidative phosphorylation pathway. Nevertheless more or less 
evident oxidative phosphorylation impairments represent the common link 
among mitochondrial pathologies clinical phenotypes arising from mtDNA 
mutations are deeply heterogeneous. The complexity of the picture is 
supplemented by the lack of a straightforward relation between genetic defect 
and clinical manifestation: mutations in different positions can lead to the 
same clinical phenotype as well as a single mutation may be associated to 
different pathologies.  
2
figure 8
Disorders that are frequently or prominently associated with mutations in a particular gene are shown in 
boldface. Diseases due to mutations that impair mitochondrial protein synthesis are shown in blue. Diseases 
due to mutations in protein-coding genes are shown in  ed. ECM denotes encephalomyopathy; FBSN 
familial bilateral striatal necrosis; LHON Leber’s hereditary optic neuropathy; LS Leigh’s  yndrome; MELAS 
mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes; MERRF myoclonic epilepsy 
with ragged-red fibers; MILS maternally inherited Leigh’s syndrome; NARP neuropathy, ataxia, and retinitis 
pigmentosa; PEO progressive external ophthalmoplegia;  PK palmoplantar keratoderma; and SIDS sudden 
infant death syndrome.
introduction
Mitochondrial Pathologies
17
A3243G mtDNA mutation, which lies within the tRNALeu gene, may be linked to 
MIDD (Maternal Inherited Deafness and Diabetes) characterized by pancreatic 
β cell dysfunction or to MELAS (Myopathy Encephalopaty Lactic Acidosis 
and Stroke-like episodes) the most common mitochondrial encephalo-
myopaty [42].  Although most of the mitochondrial pathology manifests with 
neurological symptoms, every syndrome is characterized by a peculiar set of 
clinical signs: as MELAS also MERRF (Myoclonic Epilepsy with Ragged Red 
Fibers) is associated with a point mutation in mitochondrial gene encoding 
the tRNALys but in this case the effects of mutation are completely different. 
Immunohistochemical evidence suggest that MELAS mutation is abundant in 
the walls of cerebral arterioles [50], while MERRF mutation is abundant in the 
olivary nucleus of the cerebellum [51], suggesting that the different sympotoms 
may be due to a different distribution of mutated mtDNA. However, these data 
fail to explain what directs each mutation to a particular area of the brain and 
how mutation correlates with clinical syndrome.
Part of the variability associated to these pathologies can be attributed to 
the peculiar rules of mitochondrial genetics; most of the pathogenic mtDNA 
mutations are in fact heteroplasmic in cells so that a high heterogeneity may 
exist also among tissues. 
Most of the informations regarding pathologies associated to mutations in 
mtDNA derive from studies on cybrids (cytoplasmic hybrids) [52]. Cytoplasmic 
hybrids are obtained by fusing an immortalized cell line depleted of its own 
mtDNA (ρ0 cells) with cells, usually obtained from patients, depleted of 
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nucleus. The resulting cybrids will carry nuclear genetic information deriving 
from the immortalized cell and mitochondrial genetic information arising from 
the patient, so that the mitochondrial mutations effects can be analyzed in a 
context of “neutral” nuclear background. Furthermore, this model allows to 
select cell lines with different percentage of heteroplasmy providing a useful 
system to study the correlation between mtDNA mutation load and biochemical 
phenotype. 
Analysis of different mtDNA mutations in cybrids has allowed to enlighten the 
existence of a threshold effect for the expression of biochemical phenotype.
The threshold effect indicates that a minimal quantity of mutated mtDNA 
is required to determine a clinical manifestation and this value may vary 
depending on mutation pathogenicity, tissue metabolism and cell metabolic 
status determining part of the unpredictability that characterizes these 
pathologies. The existence of a threshold for the clinical phenotype is actually 
determined by the existence of a biochemical threshold: there must be a 
minimal amount of mutated protein, or RNA in order to establish impairment 
in mitochondrial function. 
A good example of threshold effect is given by mtDNA point mutations in 
ATP6 gene at nucleotide 8993: this mutation is associated with either NARP 
(Neuropathy Ataxia and Retinitis Pigmentosa) when tissue heteroplasmy is 
lower than 90-95% or with lethal childhood Leigh syndrome, a more severe 
progressive encephalopathy, when it is present at higher percentage [53].
The existence of a threshold implies that, physiologically, rRNAs, tRNAs and 
oxphos complexes are more than it is required to permit a “sufficient” oxidative 
phosphorylation; this reserve of molecules may represent a protective 
mechanism providing a safety margin against the effects of deleterious 
mutations [54]. Also at biochemical level the presence of wild type mtDNA 
molecules may support physiological cell requirements and compensate for the 
deleterious effect of a mutation until the number of normal mtDNA decreases 
under a threshold value or until the metabolic status of the cell, i.e. its energy 
requirements, becomes more challenging for mitochondria. The networked 
mitochondrial organization represents another potential compensative 
system against pathogenic mutations: mitochondria fusion results in mixing 
of not only the outer and the inner membrane but also of mitochondrial matrix 
molecules; mitochondria fused together might exchange genes products 
so that the overall mitochondrial function in cell can be preserved also if 
mutated DNA molecules are present. Potentially also mtDNA can mix after 
fusion: although nucleoids movement seems to be restricted compared to that 
of matrix proteins, evidence of mitochondrial DNA recombination has been 
reported [55]. Therefore, the dynamic organization of mitochondria in presence 
of mutated mtDNA molecules may lead to a condition where all mitochondria 
in a single cell contain a mixture of mutated and normal mtDNA molecules; 
a consequence of this homogeneity is that rapid drifts in mutant/wild type 
mtDNA ratio during mitotic event are avoided, and the likelihood of producing 
homoplasmic cell is reduced [42].
However, as for almost all “biological rules” also in this case there are 
exceptions that cannot fit in the threshold effect explanation. Heteroplasmy 
and threshold effect can not explain peculiarities of Leber hereditary optic 
neuropathy: mtDNA point mutations associated with this neuropathy are 
indeed homoplasmic in all tissues but clinical symptoms do not manifest until 
adulthood, the only “tissue” affected is the optic nerve and the presence of 
a pathogenic mutation does not necessarily lead to pathology. Mechanisms 
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different from the oxphos impairment directly caused by these mutations must 
modulate the manifestation of the LHON clinical phenotype. 
Nevertheless the wide variability of mitochondrial pathologies manifestations 
there are clinical signs that recur in many patients: increased concentration of 
lactic acid in blood, urine, cerebrospinal fluid, as well as in tissues is a typical 
sign of oxphos deficiency. Increased lactic acid production may result from 
pyruvate accumulation under conditions where Krebs cycle and oxphos system 
are inhibited and may lead to lactic acidosis resulting in a global disturbance 
of cellular pH [56]. Another typical “mitochondrial” hallmark, very helpful in 
diagnosis, is the presence of ragged-red fibers in muscle biopsies, index 
of massive subsarcolemmal proliferation of mitochondria typically negative 
for cytochrome c oxidase activity. In this context the increased proliferation 
might represent an attempt to overcome mitochondrial defect and achieve a 
sufficient energy production into the cell.
nDNA mutations 
mtDNA encodes only thirteen of more than thousand  proteins present in 
mitochondria [57]. All proteins required for mtDNA maintenance and expression, 
oxphos complexes assembly and synthesis of cofactors such as heme and Fe-S 
clusters are nuclear encoded and imported into mitochondria. Consequently, 
mitochondrial function is deeply dependent on nDNA and mutations in this 
genome may also lead to “mitochondrial pathologies”. Indeed, most of patients 
(80-90%) with oxidative phosphorylation deficiency harbor a nuclear mutation. 
nDNA mutations associated with mitochondrial pathologies can be classified 
in different categories and may affect oxidative phosphorylation in a direct or 
indirect way [tab1], these mutations are transmitted according to Mendelian 
rules and may lie in autosomic genes, either in recessive or dominant condition, 
or in chromosome X. 
Pathogenic mutations have been found in nuclear genes encoding oxphos 
subunits of all complexes although mutations affecting Complex III, IV and V are 
less frequent indicating a more likely incompatibility with life [58]. Mitochondrial 
pathologies may also be due to mutations in nuclear genes encoding for 
“ancillary” proteins of oxphos system: these proteins are involved in assembly 
of the various mtDNA and nDNA encoded subunits, together with their 
prosthetic groups. Mutations in nuclear genes may lead to mtDNA qualitative 
(deletions) or quantitative (depletions) alterations resulting in impairment or 
deficient synthesis of mitochondrial oxphos complexes. Impairment in the 
mtDNA integrity may be due to mutations either in nuclear genes directly 
involved in mtDNA replication and maintenance or in genes involved in the 
control of nucleotides pool in mitochondria. Mitochondrial dysfunction has 
also been linked to alterations of the cytosolic protein import system as well as 
of proteins involved in mitochondrial motility and homeostasis.  Nevertheless 
nuclear mutations are not subjected to peculiar rules of mitochondrial genetics, 
apparently overlapping genetic defects can as well lead to a broad range of 
clinical manifestations.
table 1
Classification of mitochondrial pathologies associated to nuclear DNA mutations. For detailed information 
see Mitomap.[49]
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Structural Respiratory Chain 
Defects
Gene/Protein Affected 
Function
Leigh and Leigh-like syndrome NDUFS4, NDUFS7, 
NDUFS8
Complex I
Hypertrophic cardiomyopathy and 
encephalomyopathy
NDUFS2 Complex I
Macrocephaly, leucodystrophy and myoclonic 
epilepsy
NDUFV1 Complex I
Leigh and Leigh-like syndrome FP(SDHA) Complex II
Severe psychomotor retardation and 
extrapyramidal signs
uqcrb Complex III
Non-Structural Respiratory 
Chain Defects
Autosomal dominant progressive 
external ophtalmoplegia (adPEO)
ANT1 ADP/ATP exchange
Mitochondrial neurogastrointestinal 
encephalomyopathy
TP Pyrimidine 
metabolism
Assembly Defects
Leigh syndrome SURF1 Complex IV
Cardioencephalomyopathy SCO2 Complex IV
Neonatal onset hepatic failure and 
encephalopathy
SCO1 Complex IV
Metabolic acidosis, tubulopathy 
encephalopathy and liver failure
BCS1L Complex III
Homeostasis and Import
Friedrich’s ataxia Frataxin Fe-S cluster 
metabolism
Hereditary spastic paraplegia Paraplegin Proteolytic 
processing of 
mitochondrial 
proteins
Autosomal dominant optic atrophy Opa1 Mitochondrial fusion
Progressive external 
ophthalmoplegia
POLG
ANT1
mtDNA replication,  
ADP/ATP exchange
Therapeutic Approaches 
Nevertheless is now well known that mitochondrial pathologies result 
from impairment of energetic metabolism or in the general mitochondrial 
physiology the pathogenic mechanisms leading to a so broad spectrum of 
clinical manifestations are still puzzling. The poor knowledge of pathways 
linking a mutation to one pathologic phenotype, that can actually be highly 
variable also within the same family, has not allowed a real development of the 
“mitochondrial medicine”. In spite of the improvement in the diagnostic skills, 
therapeutic treatments are still inappropriate. In a review published in 2006[59], 
after having analyzed the results of several trials of pharmacological and 
non-pharmacological treatments, the authors conclude that there is currently 
no clear evidence supporting the use of any intervention in mitochondrial 
disorders and that further research is needed to establish the role of a wide 
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range of therapeutic approaches.
Usually patients with mitochondrial pathologies are subject to symptomatic 
therapy: anticonvulsant are utilized against seizure episodes, diabetes 
responds to dietary or pharmacological treatment while cardiac failure can be 
treated with pacemaker implant. Since neuronal and muscular tissues are the 
main targets of mitochondrial pathologies exercise intolerance and weakness 
are very common and also muscular training has been regarded as a possible 
treatment. It is well known that endurance-training induces mitochondria 
biogenesis in skeletal muscle, but in presence of a mutation it may actually 
increase both mutant and wild type mtDNA [60]. On the other hand, resistance 
training induces transfer of mitochondrial templates from satellite cells to 
mature muscle: since satellite cells have usually a higher content in wild type 
mtDNA this may lower the threshold level below phenotypic expression of the 
mutation [61]. 
Pharmacological therapies are focused on removal of toxic metabolites. Lactic 
acidosis is one of mitochondria pathologies hallmarks; excess of lactic acid can 
be buffered with bicarbonate or more specifically treated with dichloroacetate 
(DCA). DCA acts as inhibitor of pyruvate dehydrogenase (PDH) kinase thus, 
in presence of dichloroacetate, PDH remains in the active form favoring the 
decarboxilation of pyruvate. However, the peripheral nerve toxicity of DCA 
does not allow long periods of treatment in patients already prone to develop 
peripheral neuropathy [58]. 
A quite diffuse strategy to bypass block in respiratory chain complexes due to 
mutations in structural genes is based on administration of artificial electron 
donors/acceptors: CoQ or analogues, ascorbate or NADH and FADH2 
precursors have been used in different pathologies but the results seem highly 
dependent on type of disorder and benefic effects do not seem so promising. 
MELAS patients treated with creatine have shown an improvement of high-
intensity activity but not of lower aerobic exercise [63]. Cytochrome c oxidase 
deficiency due to mutations in SCO2, a nuclear gene encoding a copper 
chaperone, may be rescued in vitro by copper supplementation indicating a 
potential treatment for the severe form of infantile encephalo-cardio-myopathy 
associated with this mutation [64, 65].
Since reactive oxygen species are a natural by-product of respiratory chain, 
defects on the oxphos system may also lead to oxidative stress conditions for 
the cell other than to impaired energy supply. Attempting to reduce the potential 
toxic effect of ROS several oxygen radical scavengers have been utilized in 
treatment of mitochondrial pathologies. Vitamin E and in particular CoQ and 
idebenone, its analogue, have been largely used in diseases associated to 
mtDNA mutations especially for the lack of negative side effects but data from 
controlled trial in large cohort of patients are required to demonstrate the 
reliable effect of these molecules [58]. 
The most promising, and most hard to set up, therapeutic strategy for 
mitochondrial pathologies treatment is gene therapy. The goal is to force a 
shift in heteroplasmy promoting replication of mtDNA wild type molecules or 
to replace the impaired protein function. Different approaches may be used 
to achieve the genetic control of mitochondrial metabolism. Nucleic acids 
derivatives have been used in vitro to selectively inhibit replication of mtDNA 
mutant molecules in A3844G cells [66]. Moreover, in cells harboring mutations in 
the mitochondrial tRNALys gene, that are associated to MERRF, mitochondrial 
function in both immortalized cells and primary fibroblasts has been partially 
restored by a yeast tRNA derivative capable to enter mitochondria [67].
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Effects of alterations in structural genes may be mitigated by means of allotopic 
expression, xenotopic expression or import of restriction endonucleases.  
The correct nucleotide sequence of a mutated mitochondrial gene may be 
inserted in the nuclear genome upon its linking to a mitochondrial targeting 
sequence to drive import into the organelles. This approach has been utilized 
to correct, in vitro, biochemical defect in cybrids harbouring the T8993G NARP 
mutation [68] and the G11778A LHON mutation [69].
Rescue of protein activity may be also achieved transfecting affected 
mammalian cells with mitochondrial or nuclear genes deriving from other 
organism but encoding homologue proteins (xenotopic expression). Expression 
of ATP6 gene deriving from Chlamydomonas reinhardtii, a green alga, has 
been shown to overcome deficiency in both viability and ATP synthesis in 
cybrids with T8993G NARP mutation [70].
Restriction endonucleases may be used to specifically destroy mutant mtDNA 
molecules: transient expression of the SmaI gene fused to a mitochondrial 
targeting sequence in NARP cybrids showed specific elimination of the 
mutant mtDNA followed with repopulation by the wild type mtDNA, resulting in 
restoration of both the normal intracellular ATP level and normal mitochondrial 
membrane potential [71]. The same approach has been shown to be effective 
also in vivo: in mice carrying two different mtDNA haplotypes Bayona-
Bafaluy and co-workers have shown that expression of a selective restriction 
endonuclease results in a significant shift in mtDNA heteroplasmy in muscle 
and brain [72].
Nevertheless numerous theoretically effective genetic strategies have been 
proposed, experimental data are still limited to the in vitro testing. Several 
problems have to be overcome before in vivo tests and trials may occur: 
concerning mtDNA mutations the therapeutic wild type gene products (tRNA, 
rRNA or protein) have to be selectively targeted to mitochondria and specifically 
addressed to the affected tissue. The limitations of genetic counseling caused 
by the high unstableness of mitochondrial genome further increase the 
necessity of really understanding how mitochondrial function can modulate so 
deeply and differently cell physiology in order to develop adequate therapeutic 
strategy for patients affected by these highly disabling pathologies.
figure 10
The optic nerve is a continuation of the 
axons of the ganglion cells in the retina.
figure 9 
Human eye. The fovea, also known as the 
fovea centralis, is a part of the eye, located 
in the center of the macula region of the 
retina.
optic nerve
fovea 
optic nerve
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Leber Hereditary Optic 
Neuropathy
Overview
Leber hereditary optic neuropathy (LHON – OMIM # 535000) was first described 
in 1871 by the German ophthalmologist Theodore Leber as a form of optic 
neuropathy maternally transmitted and prevalently affecting young males. The 
endpoint of the pathology is usually optic nerve atrophy with bilateral loss 
of vision; the mean age of onset of pathology is between 27 and 34 years 
with a range of 1 to 70 years [11] but 95% of carriers who will experience 
visual failure will do so before the age of 50 years [73]. At presymptomatic 
stage LHON manifests with signs of ocular vascular alteration such as 
peripapillary telangiectatic microangiopathy; visual loss takes place in 
the acute stage affecting either synchronously both eyes at onset or 
asymmetrically first one eye and then the other with an average 
time interval between affected eyes of 1.8 months [74]. At the end 
stage the retinal nerve fiber layer degenerates leading to optic 
atrophy in few months. 
One of the striking characteristics of LHON is the apparently 
absolute involvement of retinal ganglion cells (RGC) whose 
axons form the optic nerve. RGC are neuronal cells distributed 
in a non-linear way in the inner surface of retina where they are 
particularly concentrated in the perifoveal macula [fig 9]. Further 
from fovea the number of RGC decreases becoming relatively 
sparse in the periphery. Other than for distribution RGC differ also 
for the size: those near fovea are smaller with smaller caliber axons.
The axon of each retinal ganglion cell travels through nerve fiber layer 
(NFL) toward the optic nerve head. There, the fibers make an orthogonal turn 
and pierce lamina cribrosa to form optic nerve. Only posterior lamina cribrosa 
the axons become myelinated [fig 10] acquiring a greater efficiency respect to 
unmyelinated portion that has a much slower conduction velocity and requires 
greater energy to restore the electrical potential [75]. 
Mitochondria distribution matches the energy and functional requirements of 
these axons: NFL and prelaminar-laminar RGC axons are characterized by 
intense COX staining, index of intense oxidative phosphorylation, 
that decreases with the appearance of myelin [76].
In optic nerve degeneration observed in LHON patients 
temporal fibers of papillo-macular bundle (PMB) 
characterized by small caliber and thin myelin sheath are 
the first and most severely affected whereas the nasal 
fibers seemed to be partially spared in late stage of the 
disease [76]. 
Nevertheless loss of central vision is mostly permanent, a 
few cases of spontaneous recovery of visual acuity have been 
reported. Vision may improve progressively or sometimes suddenly, 
with contraction of scotoma or reappearance of small islands of vision 
within it (fenestration) [76]. The probability of visual recovery seems to be 
linked to genetic background and age of onset as well as to thickness of 
retinal nerve fiber layer [77].
The maternal pattern of LHON inheritance was confirmed on 1972 by Erickson 
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who proposed the presence of a mutation in the mitochondrial DNA [78] but only in 
1988 Wallace and colleagues identified the first mitochondrial pathogenic point 
mutation in nine pedigrees with a clinical diagnosis of LHON: this mutation 
is located at nucleotide position 11778 of mtDNA and converts an highly 
conserved arginine to histidine at codon 340 in the NADH dehydrogenase 
subunit 4 (ND4) of Complex I of the respiratory chain [48]. 
Since then a plethora of mtDNA mutations has been found in different LHON 
patients but now it is well established that at least 90% of LHON families 
harbor one of the three so called primary mutations all affecting mitochondrial 
genes encoding subunits of Complex I of the respiratory chain: G11778A ND4 [48], 
G3460A ND1 [79], T14484C ND6 [80]. 
Although the majority of LHON families carry the mtDNA pathogenic mutations 
in the homoplasmic condition, i.e. all mtDNA molecules in all tissues are 
mutated, not all maternally related individuals develop the pathology. Therefore, 
the presence of a LHON mtDNA mutation is necessary but not sufficient for 
LHON clinical manifestation. 
Penetrance of the disease seems dependent on the point mutation: only half 
of the G11778A index patients had a history of similar affected relatives while 
the proportion is higher for G3460A (71%) and T14484C (100%) patients [64]. 
An intriguing feature of LHON is the gender bias: 30-50% of males but only 
5-10% of females who harbor one of the three primary mutations actually 
develop the optic neuropathy [74]. The incomplete penetrance and the gender 
bias imply that additional genetic and/or environmental factors must modulate 
the phenotypic expression of LHON. However, the gender bias could also 
result from a combination of subtle anatomical, hormonal and physiological 
variations between males and females [73]. 
The existence of further genetic determinants in LHON has been largely 
investigated. Because of male prevalence chromosome X has been analyzed 
for putative LHON-related genes. A linkage analysis in an extended Brazilian 
family carrying the G11778A LHON mutation as well as a large study in 
LHON European families revealed the existence of X-linked loci [81, 82] but 
the real involvement of chromosome X in LHON penetrance still need to be 
elucidated. 
Genetic polymorphisms of nuclear genes involved in oxidative stress response 
and in apoptosis have been as well investigated in LHON G11778A patients. 
LHON patients carrying an oxidative-stress related polymorphism in the EPHX1 
gene - encoding a microsomal epoxide hydrolase - or an apoptosis-related 
polymorphism in the TP53 gene - encoding the onco-protein p53 - developed 
pathology earlier than did those without these genetic trait [73] suggesting that 
increased vulnerability to oxidative stress or to apoptosis might contribute to 
exacerbate the pathology.
Mitochondrial genetic background has been also considered as a possible 
risk factor for LHON penetrance modulation. Haplogroups are defined as 
mitochondrial DNA variants characterized by several common polymorphisms 
reflecting the evolutionary history of mtDNA differentiation: the “neutral” 
mutations contained in a specific haplogroup could modulate mitochondrial 
diseases expression either exacerbating or protecting from mutations 
deleterious effect. 
Several studies have been focused on the possible correlation between LHON 
and mtDNA haplogroups. Analyzing LHON pedigrees haplogroups of different 
European origin a higher frequency of haplogroup J was observed in patients 
carrying the G11778A and T14484C mutations with respect to controls. 
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Haplogroup J is characterized by polymorphisms in two genes encoding 
Complex I subunits: T4216C in ND1 gene and G13708A in ND5 gene. 
Even though these genetic variants do not further impair the respiratory chain 
activity in G11778A cell the hypothesis is that their presence might be related 
to alterations in the structure or function of Complex I that could cooperate in 
disease manifestation. Unlike the other two primary LHON mutations G3460A 
is distributed in all haplogroups at frequencies similar to the control population [76, 77].
The last factor that could modulate LHON expression is the environment. Five 
pairs of monozygotic twins harboring a primary LHON mutation have been 
reported in the literature and in two cases the twins have remained discordant. 
Although there is always the possibility that the unaffected sibling will lose 
vision later on his life, the existence of discordant monozygotic twins strongly 
suggests that non-genetic factors also contribute to LHON penetrance [73]. 
The contribution of environmental factor is supported by the fact that clinical 
manifestations of toxic and nutritional neuropathies are similar to that observed 
in LHON [77]. 
Several studies have as well been focused on tobacco and alcohol consumption 
but the results are controversial. Conflicting conclusion have also been reached 
regarding nutritional deprivation, exposure to industrial toxins, antiretroviral 
drugs, psychological stress or acute illness. 
The role of environmental risk in LHON still remains unclear: in order to obtain 
reliable epidemiological data there is the necessity to collect sufficient number 
of subjects. Moreover environmental factors might have different impact on 
different LHON pedigrees depending, for example, on the mtDNA background 
of the family. 
However, besides the genetic and environmental issue, the principal 
unanswered question in LHON is the pathogenic mechanism that link 
mutations in Complex I subunits with a specific pattern of retinal ganglion cells 
degeneration in a context of highly variable penetrance and gender bias. 
Complex I
Complex I in bovine heart is composed of 46 subunits for a molecular weight 
of about 1000 KDa, representing the biggest and the less known complex of 
the respiratory chain. This multi-subunit complex catalyzes electron transfer 
from NADH to CoQ through a flavoprotein and a Fe-S clusters series. 
Contextually, Complex I drives a vectorial proton transport from the matrix to 
the intermembrane space contributing to the electrochemical gradient mostly 
used by ATP synthase to form ATP from ADP and inorganic phosphate.
In eukaryotes Complex I has a dual genetic origin: in mammalian seven 
subunits (ND1-ND6, ND4L) are indeed codified by mitochondrial DNA while 
the remaining subunits are nuclear gene products.
Due to its size and hydrophobicity the enzyme has not yet been crystallized 
but some information about its structure and function derives from electronic 
microscopy analysis and homology studies. Complex I is a L-shape multi-
protein complex composed of an hydrophobic arm embedded in the inner 
mitochondrial membrane and an hydrophilic arm exposed to the matrix. The 
L-shape is well conserved from prokaryotes to eukaryotes [fig 11]. 
In bacteria a simple form of proton pumping NADH:Ubiquinone oxidoreductase 
is composed of fourteen subunits yielding a complex of 550 KDa [83]. In 
eukaryotes the corresponding “core”, representing the functional unit of the 
figure 11
Complex I 3d structure of E. Coli, N. Crassa and B. Taurus
26
enzyme, consists of all the seven mitochondrial encoded subunits localized 
in the hydrophobic arm and seven nuclear encoded subunits containing all 
the known redox prosthetic groups, namely one molecule of flavine adenine-
mononucleotide (FMN) and eight bi- or tetranuclear iron-sulfur clusters 
(N1a,N1b,N2-N6a,N6b) [84] [tab 2]. The remaining subunits are defined 
“accessory” and are supposed to be involved in assembling and/or regulation 
of the complex activity. However, a novel role for “non-core” subunits as 
regulatory molecules outside the mitochondrial compartment is now emerging. 
Moreover some accessory subunit could take part to additional metabolic routes 
as suggested by the presence of a mitochondrial acyl carrier subunit and a 
NADPH binding site in the 39 KDa subunit [85]. In this context a good example 
is given by NDUFA13 subunit, a complex I subunit localized in the matrix arm. 
NDUFA13 is also known as GRIM-19 (gene associated with retinoid-interferon-
induced mortality 19). The gene was indeed cloned for the first time during a 
screening for genes required for interferon-beta- and retinoic acid-induced 
cell death in a mammary carcinoma cell line. Only later the protein was found 
as part of mitochondrial Complex I [11] showing a dual function for GRIM-19: 
one in the oxphos system as structural component of Complex I, the other as 
part of the apoptotic pathway. Complex I subunit as GRIM-19 might represent 
the actual link between mitochondria and nucleus: in this case Complex I 
structure/activity would not be limited to energy production but will be involved 
in the overall cell physiology as “sensor” of cell wellness.
Some information about Complex I structural organization comes 
from fractionation experiments that have shown that the mitochondrial 
NADH:Ubiquinone oxidoreductase enzyme can be separated in three major 
component. The hydrophilic arm is represented by subcomplex Iλ, which 
contains the Fe-S clusters and the flavoprotein fraction. The membrane arm 
can be fractionated in an hydrophobic module called Iβ and in a connecting 
module called Iγ. The Iγ module contains the mitochondrial encoded subunits 
ND1, ND2, ND3, ND4L and the nuclear encoded subunit KFYI [86, 87]. In a 
previous study the bovine Complex I fractionation resulted in two fragments: 
Iα and Iβ. Iα represents the hydrophilic arm of the Complex plus the fourteen 
subunits of Iγ, while Iβ corresponds to the hydrophobic arm [87] [tab 2 and fig. 12].
The “stalk” connecting the two arms on Complex I has been characterized 
in E. Coli. This portion is supposed to be involved in electrons transfer from 
the NADH binding site in the hydrophilic arm to the CoQ binding site in the 
membrane [88]. The stalk moiety in E.Coli is composed by NuoB, NuoCD and 
NuoI subunits corresponding to PSST, 49+30 KDa and TYKY subunits in 
bovine [89]: TYKY contains Fe-S clusters N6a and N6b while Fe-S cluster N2 
is supposed to be localized in the PSST subunit [90].
As the molecular structure also the electron transfer and the proton pumping 
mechanisms in Complex I are not yet completely understood. The Complex I 
substrate NADH reduces FMN; from FMN electrons flow through Fe-S clusters 
Human 
Gene
Bovine 
homologue 
Subcomplex
ND1  ND1 Iγ
ND2  ND2 Iγ
ND3  ND3 Iγ
ND4  ND4 Iβ
ND4L  ND4L Iγ
ND5  ND5 Iβ
ND6  ND6 Iα
NDUFV1  51 kDa Iγ
NDUFV2  24 kDa Iγ
NDUFV3  10 kDa Iγ
NDUFS1  75 kDa Iγ
NDUFS2  49 kDa Iγ
NDUFS3  30 kDa Iγ
NDUFS4  18 kDa Iγ
NDUFS5  15 kDa Iα
NDUFS6  13 kDa Iλ
NDUFS7  PSST Iλ
NDUFS8  TYKY Iλ
NDUFA1  MWFE Iα
NDUFA2  B8 Iλ
NDUFA3  B9 Iα
NDUFA4  MLRQ nd
NDUFA5  B13 Iλ
NDUFA6  B14 Iα
NDUFA7  B14.5a Iλ
NDUFA8  PGIV Iα
NDUFA9  39 kDa Iα
NDUFA10  42 kDa Iα (loosely)
NDUFA11  B14.7 Iα
NDUFA12  (DAB13) B17.2 Iλ
NDUFA13  (GRIM-19) B16.6 Iλ
NDUFB1  MNLL Iβ
NDUFB2  AGGG Iβ
NDUFB3  B12 Iβ
NDUFB4  B15 Iα & Iβ
NDUFB5  SGDH Iβ
NDUFB6  B17 Iβ
NDUFB7  B18 Iβ
NDUFB8  ASHI Iβ
NDUFB9  B22 Iβ
NDUFB10  PDSW Iβ
NDUFB11  (NP17.3) ESSS Iβ
NDUFAB1  SDAP Iα & Iβ
NDUFC1  KFYI Iγ
NDUFC2  B14.5b Iβ
??  (10.6 kDa) 
table 2 and figure 12
Subunit composition of mammalian Complex I.
The subunits that compose the core unit of the complex are indicated in bold [87].
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with an unknown sequence. The CoQ electrons donor 
seems to be the Fe-S cluster N2 even though it seems 
localized quite far from the CoQ binding site. Two options 
have been proposed to solve the problem of the distance 
between CoQ and N2 cluster: 1) in the connecting region 
there would be an hydrophobic or amphipathic ramp that 
consent to CoQ to diffuse out of the membrane arm to 
reach its reductant, 2) large scale conformational changes 
could bring cluster N2 closer to the membrane domain 
and then closer to CoQ binding site [85, 91].
During the years different hypotheses have been proposed 
to explain Complex I proton pumping activity but most 
likely the redox chemistry drives proton translocation via 
a conformational mechanism. Since the redox reactions 
take place exclusively in the hydrophilic arm the energy 
for proton translocation must be transduced to the proton 
pumping moiety in the membrane arm via conformational 
coupling [85, 91]. Likely one or more of the mitochondrial-
encoded subunits (ND1-ND6 and ND4L) are part of the 
proton pumping machinery. Subunits ND2, ND4 and ND5 
show some homology to Na+/H+ antiporters and have 
therefore be proposed as involved in proton translocation 
[91]. Several mutational studies show that dysfunctions 
in ND1, ND4L, ND4 and ND6 [93, 94, 95, 96] subunits affect 
ubiquinone reductase activity indicating a contribution 
of hydrophobic subunits to ubiquinone binding or simply 
reflecting the tight coupling between redox chemistry and 
proton pumping activity [85]. 
The complexity of this enzyme is further increased 
by several mechanisms by which its activity could be 
regulated. Complex I is regulated by post-translational 
modifications: the 18-kDa IP subunit, encoded by 
NDUFS4 gene localized in chromosome 5, is involved 
in the normal assembly of the complex and mediates, 
through its phosphorylation by PKA, regulation of complex 
activity by the cAMP cascade [97]. 
A pivotal role in Complex I function may be played by 
mitochondrial membrane lipids: a tightly bound cardiolipin 
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may be required for structural integrity of the complex, an maybe for the 
supramolecular organization, while the amounts of the more weakly bound 
phosphatidylcholine and phosphatidylethanolamine seem modulate the 
catalytic activity [98]. 
As previously reported, Complex I is also the major source of mitochondrial 
superoxide anion. Nevertheless in physiologic conditions the electron leak from 
Complex I redox centers is very low, there are evidences showing enhanced 
ROS production in presence of defective Complex I, suggesting that structural 
modification of the enzyme may play a crucial role in inducing oxidative stress 
in cell [99]. Complex I defects are indeed associated with a wide group of clinical 
disorders, ranging from neonatal to adult onset neurodegenerative diseases: 
besides LHON, cardio- and encephalomyopathies as well as some form of 
Parkinson’s disease can derive from Complex I deficiencies that seem to play 
a main role also in aging process [100, 101].
The physiological role of additional functional aspects of Complex I like ROS 
production or apoptosis regulation is even less understood than the redox or 
proton pumping activity but these aspects are of great interest because of the 
role of Complex I in several human diseases. 
LHON Biochemical features  
LHON primary pathogenic mutations affect mitochondrial genes encoding 
subunits located in the membrane sector of Complex I. The G3460A transition 
in the mitochondrial ND1 gene converts the modestly conserved alanine 
52 to a threonine (A52T). The ND4 G11778A mutation changes the highly 
conserved arginine at amino acid 340 to a histidine (R340H) while the ND6 
T14484C mutation changes the weakly conserved methionine at amino acid 
64 to a valine (M64V).
Several other mutations have indeed been associated to LHON or LHON plus 
dystonia phenotypes and most of them localized in ND1 and ND6 genes that 
are considered mutational “hot spots” [102 ,103]. ND1 mutations have also been 
reported in Alzheimer’s disease and Parkinson’s disease [11] further confirming 
that Complex I alterations play a pivotal role in neurodegeneration.
The function of the mutated Complex I subunits in LHON patients is not 
completely understood. Some study has shown that ND4 and ND6 subunits 
are essential for the assembly of other ND subunits into the complex [104], 
the same could be for ND1 subunit which mutations may lead to a severe 
reduction of holocomplex I levels [87]. As above-mentioned homology of ND4 
subunit with bacterial antiporters indicates that it might play a role in the proton 
pumping activity.
Because of the genetic origin of the pathology, the first and most investigated 
hypothesis regarding LHON pathogenic mechanism has been the bioenergetic 
failure. Alterations in Complex I activity might indeed reflect in a decreased ATP 
production leading to a condition of reduced energy availability for the cell.  
Neurons are indeed highly depending on ATP supply not only for 
neurotrasmission but also for correct localization of mitochondria:  in retinal 
ganglion cells as in other nervous cells mitochondrial biogenesis takes place 
only in the soma from where mitochondria need to be addressed along the 
axons through an ATP-dependent mechanism [4]. Impairment in ATP production 
may thus reflect also in altered distribution of mitochondria: in RGC axons this 
phenomenon may be highly relevant in the non-myelinated portion of optic nerve.
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Different cellular models have been used to study the energetic status in LHON 
and conflicting results about the extent of oxphos impairment associated to 
LHON mutations have been produced. 
In cybrids carrying each of the three LHON primary mutations only the Complex 
I-driven ATP synthesis and oxygen consumption rate have been reported to be 
consistently affected while the succinate-driven ATP synthesis and respiration 
were not impaired [105]. Interestingly these cells may effectively compensate 
the oxphos failure through ATP synthesis sustained by alternative pathways 
such as glycolysis [105].
According to this, in vivo results obtained using the 31P magnetic resonance 
spectroscopy (MRS) in LHON patients show a defective ATP synthesis in 
skeletal muscle and/or brain [106, 107].  
However, lymphocytes from patients harboring the G11778A mutations does 
not show differences from controls in terms of energy charge, i.e. the relative 
proportion between ATP, ADP and AMP [108] and in fibroblasts harboring the 
G3460A mutations the Complex I-linked ATP synthesis was found to be normal [109].
In LHON cybrids shows that the total cellular ATP content has been shown to 
decreas respect to controls only when the cells are grown in metabolic stressed 
conditions, i.e. in galactose medium [110], suggesting that the biochemical effect 
might arise only in conditions of high energy demand.
The discrepancy of results obtained studying the oxphos system in different 
models might be not so unexpected: all experiments have indeed been 
performed in cellular models different from the real target of the pathology and 
the energy demand and consequently the pathogenicity of the mutation might 
be completely different from that of retinal ganglion cells (RGC). Moreover, 
the observed variability could further confirm the existence of the above-
mentioned genetic or environmental modulating factor that reduce the chance 
to obtain according results.
Besides the controversial role of energy failure, an important issue about 
LHON pathogenesis is the apoptotic death that almost simultaneously 
hits retinal ganglion cells leading to optic nerve atrophy. The programmed 
death mechanism hypothesized by the absence of inflammation signs at 
histopathological exam has been also confirmed by biochemical analysis. 
Different studies on LHON cybrids grown in galactose medium have shown 
that these cells are more prone to apoptotic death respect to control. Under this 
culture condition, the slow metabolism of galactose to glucose-1-phosphate 
is not sufficient for the cell to synthesize the bulk of ATP requirement by 
glycolysis, and cells are forced to rely on respiratory chain for ATP synthesis.
The increased release of cytochrome c into the cytosol in LHON cybrids 
grown in absence of glucose indicates that mitochondria are involved in 
the activation of apoptotic pathway [111]. Moreover, the apoptotic cell death 
of LHON cybrids grown in the same culture conditions has been shown to 
be caspase-independent and mediated by AIF (Apoptosis Inducing Factor) 
and endonuclease G [110]. However, although it has been established that 
degeneration of RGC in LHON occurs through apoptotic pathway, the 
connection between Complex I dysfunction and apoptotic commitment still 
remains not understood.
In the last years, several reports have shown the likely existence of a third 
factor involved in LHON pathognesis: there is in fact mounting evidence that increased 
ROS production and oxidative stress may have a pivotal role in optic nerve 
degeneration. 
Complex I is the major source of superoxide anion and alterations in its function 
figure 13
Diagram of the mammalian mitochondrion showing the relationship between energy production, ROS 
generation, and regulation of apoptosis [49].
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might be reasonably linked to an increased production of O2• – and to an unbalance 
in the redox status of the cell. The possibility that LHON mutations affect the 
interaction of Complex I with CoQ [76] further supports the role of oxidative stress 
in pathogenic mechanism: CoQ partially reduced molecules are actually another 
potential source of reactive oxygen species [112]. 
In a cellular model similar to RGC it has been shown that these cells might differ 
from other kind of neurons in the production of superoxide. Moreover, mitochondria 
from RGC-like cells show a minor content of ETC complexes, in particular Complex 
I, and a minor content of MnSOD respect to brain mitochondria [113]. Although in the 
work superoxide production is deduced from hydrogen peroxide production still the 
author has demonstrated that RGC-like cells have a minor content of mitochondrial 
ROS with respect to brain and neuroblastoma mitochondria supporting the 
hypothesis that retinal ganglion cells might be very vulnerable also to slight shift in 
the ROS production/scavenging equilibrium. Several other papers demonstrate the 
importance of oxidative stress in this particular optic neuropathies. Lymphocytes 
from LHON patients treated with the oxidizing agent 2 deoxi-D-ribose showed a 
significant increase in the percentage of apoptotic cells with respect to controls [114] 
while in mice inoculation into the eyes of a rybozime that reduces MnSOD mRNA 
and protein level induces loss of axons and myelin in the optic nerve, the hallmarks 
of optic nerves examined at autopsy of LHON patients [115]. 
LHON cybrids obtained by a neuronal precursor cell line have shown higher ROS 
production with respect to controls only upon differentiation in neuronal mature cell 
indicating that LHON mutations might require a differentiated neuronal environment 
in order to induce oxidative stress [116].
Concerning the male prevalence in LHON interesting information has been 
brought by a study carried out in rats: female mitochondria have been reported 
to be less prone to oxidative stress respect to male mitochondria thanks to a 
higher expression of antioxidant enzymes that may be modulated by estrogens 
[117]. These results might represent the effective link between oxidative stress and 
gender bias in LHON providing another evidence of ROS relevance in disease 
pathogenic mechanism.
At present time, the plethora of information regarding LHON biochemical features 
allow to hypothesize a pathogenic mechanism resulting from a complex combination 
of energy production deficiency, oxidative stress and apoptosis that is supported 
by the several interconnecting points that link these three processes [fig 13]. 
Basic Domain
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figure 14
OPA1 gene structure. The exons are indicated by numbers.
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Autosomal Dominant Optic 
Atrophy
Overview
Autosomal dominant optic atrophy (ADOA), also known as Kjer’s disease 
(OMIM # 165500) is the most common form of inherited optic atrophy, with a 
frequency of 1:12000 to 1:50000 [118]. The disease is characterized by moderate 
to severe loss of visual acuity with insidious onset in early childhood, temporal 
optic disc pallor, impairment in the color vision and central scotoma [119]. The 
disease progression may be quite variable also within the same family, ranging 
from mild cases with visual acuity that stabilizes in adolescence, to slowly but 
constantly progressing cases, to cases with sudden, step-like decreases of 
visual acuity. Despite the remarkable difference of the clinical evolution, the 
endpoint of the pathological process in ADOA is clinically indistinguishable 
from LHON. Histopathological and electrophysiological studies suggest that 
also in this form of neuropathy the underlying defect is retinal ganglion cell 
degeneration associated with optic atrophy. Although LHON has a sudden 
onset of visual loss in both eyes and appears at a later age (27-34 years), in 
atrophic phase it is difficult to distinguish LHON from ADOA without a family 
history: in both pathologies optic nerve shows axonal loss and demyelination, 
with the smallest fibers of papillo-macular bundle being the most vulnerable, 
and absence of inflammatory reaction [120].
ADOA is transmitted according to Mendelian rules in an autosomal dominant 
manner; the majority of families are linked to the chromosome 3q28-29 
locus where in 2000 a new gene, encoding a dynamin-related protein that 
is localized in mitochondria (OPA1), has been found to segregate with the 
disease [121 122]. 
Thus, ADOA represents the second case of pathology in which a single 
cellular type, the same of LHON, is affected. As for Complex I in LHON, also 
the nuclear gene linked to ADOA encodes a mitochondrial protein ubiquitously 
expressed: while most abundant in the retina, the OPA1 mRNA and protein 
are in fact widely distributed in several tissues [121]. 
About a hundred OPA1 gene mutations associated to ADOA have been 
described so far: most of them are nucleotide substitution, but also deletions 
and insertions are spread throughout the coding sequence of the gene, 
although the majority is localized in the GTPase domain and in the 3′ end [118, 
119] [fig14]. 
Almost 50% of the OPA1 mutations cause premature truncations and nearly 
40% are located within the GTPase domain. They are therefore supposed to 
4
GTPase Middle PH GED PRD
figure 15
Schematic diagram of the domains within dynamin-like protein. Dynamin consists of five distinct domains: 
the GTP hydrolysis domain (GTPase), a middle domain, a pleckstrin homology domain (PH), a GTPase 
effector domain (GED), and a highly basic C-terminal proline-rich domain (PRD).
32
lead to the loss of protein function providing indications that haploinsufficiency 
is the cause of the disease [123]. Although haploinsufficiency is, so far, the more 
likely effect of OPA1 mutations a dominant negative effect cannot be ruled 
out: indeed, dynamins with deficient GTPase activity can form oligomers with 
the wild type protein interfering with its GTPase activity [124]. Olichon and co-
workers studying the effect of different OPA1 mutations have proposed that 
those occurring in the GTPase domain would exert a dominant negative effect, 
while the C-terminal truncations, by removing the potential GED domain and 
thus abolishing the oligomerization-stimulated activity of the dynamin, would 
cause haploinsufficiency [118]. 
Besides the poor knowledge of the pathomechanisms leading to impairment 
of Opa1 function in ADOA as well as in LHON the link between genotype 
and phenotype is not clear: the variable penetrance suggest that other 
still unknown genetic or environmental factors might play a role also in the 
phenotypic expression of OPA1 gene mutations.
OPA1
OPA1 (optic atrophy-1) gene encodes a dynamin-related protein showing 
GTPase activity and well conserved during evolution: Mgm1 and Msp1 
represent the Opa1 orthologues in S. cerevisiae and in S. pombe, respectively, 
as demonstrated by complementation of Msp1 loss by OPA1 expression[125].
In human the gene structure comprises 31 exons and consists of a N-terminal 
mitochondrial targeting sequence followed by short hydrophobic stretches, 
a coiled-coil domain, a GTPase domain, a middle domain and a C-terminal 
coiled-coil domain known as GTPase Effector Domain (GED) [126] [fig.15]. 
The gene expression may result in 2-5 different electrophoretic forms of 
Opa1 deriving from different proteolytic cleavage; at translational level eight 
alternative splicing mRNAs derive from different combination of exons 4, 4b 
and 5b [11, 126]. Two intramitochondrial proteases, the rhomboid-like PARL 
(presenilin-associated rhomboid-like protein) and the paraplegin, have shown 
to be involved in Opa1 proteolytic cleavage, either to control the apoptotic 
process or the mitochondrial morphology [127, 128]. The proteolytic processing 
of Opa1 has a counterpart in yeast: Mgm1 is as well proteolytically processed 
into long (l-Mgm1) and short forms (s-Mgm1) by a rhomboid-like protease. 
l-Mgm1 is integrated in the inner mitochondrial membrane, while s- Mgm1 is 
released in the intermembrane space; these two forms of Mgm1 seem play 
overlapping as well distinct roles in maintaining mtDNA, remodeling cristae 
and fusing mitochondria [129].
Moreover, has been reported that decreased mitochondrial ATP levels, either 
generated by apoptosis induction, ΔΨ dissipation or ATP synthase inhibition, 
is the common and crucial stimulus that controls OPA1 processing suggesting 
that the Opa1 ATP-dependent cleavage plays a central role in correlating 
the energetic metabolism to mitochondrial dynamic [130]: cells might use this 
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mechanism to monitor the ATP level and use this functional readout to inhibit 
the fusion of defective mitochondria.
Nevertheless the sub-mitochondrial localization of this protein has long 
been subject of controversy it is now well accepted that Opa1 is active in 
the intermembrane space although its relationship with the mitochondrial 
membranes is not still completely clear. Evidences show that Opa1 co-
sediments with both membranes and interacts more or less tightly with the 
inner membrane [130, 131]. The discrepancies regarding Opa1 localization might 
be justified by the existence of several isoforms that could have  different sub-
localizations and functions. 
OPA1 is expressed in the myelinated regions of the human optic nerve, 
which show a decreased number of mitochondria as compared to the soma 
of the RGC, where biogenesis of mitochondria occurs, and to the fiber layer 
containing unmyelinated axons before the lamina cribosa [133]. 
Information regarding Opa1 function derives basically from in vitro experiments 
suppressing or over-expressing the protein; Opa1 is involved in mitochondrial 
fusion and in inner membrane remodeling, a process of primary relevance in 
regulation of apoptosis but the real mechanisms underlining its functions need 
to be still clarified. 
Modulation of OPA1 expression may have different consequences depending 
on the cellular type: overexpression in cells with tubular mitochondria induces 
fission of mitochondrial network while in cells with physiologically punctuated 
mitochondria increased OPA1 expression induces mitochondrial fusion [134].
In yeast, the absence of Mgm1, the Opa1 orthologue, determines profound 
distortion of cristae shape, lack of growth in presence of aerobic substrates 
and formation of “petite” colonies characterized by mtDNA loss or 
rearrangements[135]. Mgm1 acts in concert with Fzo1 and Ugo1 to counteract 
mitochondrial fission and although the mammalian homologue of Ugo1p 
has not yet been identified, Fzo1p orthologues have been characterized 
in mitofusin1 and 2 (Mfn1, Mfn2). The same mechanism seems to be also 
preserved in mouse fibroblasts. In fact in Mfn1 deficient cells Opa1 cannot 
promote mitochondrial fusion, the defect being complemented by reintroduction 
of Mfn1 but not Mfn2, unequivocally identifying outer membrane Mfn1 as an 
essential functional partner of Opa1 [136].  Furthermore, it has been shown 
that cells lacking both Mfn1 and Mfn2 completely lack mitochondrial fusion 
and show severe cellular defects, including poor cell growth, widespread 
heterogeneity of mitochondrial membrane potential, and decreased cellular 
respiration [137]. Disruption of OPA1 by RNAi blocked as well mitochondrial 
fusion and resulted in similar cellular defects [137].
A recent study aimed to determine the function of the different Opa1 isoforms 
has partially clarified the role of OPA1 exons that undergoes alternative 
splicing. The presence of exon 4 in Opa1 determines functions associated 
with both ΔΨ maintenance and fusion of mitochondrial network while exons 
4b and 5b do not contribute to these processes [126]. Overexpression of Opa1-
5b induces the classic apoptotic cascade with complete cytochrome c release 
before nuclear fragmentation while silencing of Opa1 variants containing 
exons 4b or 5b induces apoptosis without relevant release of cytochrome c 
and without mitochondrial network fission or major modification of the cristae 
structure [126]. There are other evidences suggesting that Opa1 apoptosis 
regulation might be not linked to its pro-fusion activity. In mouse fibroblasts has 
been demonstrated that oligomerization of two forms of OPA1 - one soluble 
and intermembrane space-located and the other one embedded in the inner 
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membrane - controls the tightness of cristae junctions preventing cytochrome 
c release and protecting from apoptotic death; interestingly, mitofusins seem 
not required for the antiapoptotic effect of OPA1 [138].
Recently has been reported that mutations in OPA1 can also be responsible 
for an ADOA “plus” phenotype with sensorineural deafness, ataxia, axonal 
sensory-motor polyneuropathy, chronic progressive external ophthalmoplegia 
and mitochondrial myopathy with cytochrome c oxidase negative and ragged 
red fibers [139]. These particular patients, all harboring missense mutations in 
OPA1, are characterized also by multiple deletions of mitochondrial DNA in 
their skeletal muscle, thus revealing a new role of the Opa1 protein in mtDNA 
stability [139], strongly recalling one of Mgm1 functions in yeast. 
Mitochondrial function has been analyzed in fibroblasts deriving from ADOA 
patients carrying different OPA1 mutations all leading to a truncated form of 
protein: only in galactose medium, i.e. under forced oxidative metabolism, a 
significant impairment in mitochondrial ATP synthesis driven by Complex I 
substrates was found. Furthermore, growth in galactose medium has been 
shown to inhibit mitochondrial fusion in ADOA fibroblasts, but not in control 
cells [140], indicating that impairment in the energy supply might be involved in 
the pathomechanism of ADOA. 
Fission & Fusion 
Mitochondria do not exist as free-floating vesicles in cytoplasm but as a 
filamentous network that extends throughout the cell. Mitochondrial network 
is a dynamic entity capable to respond to variations in cell metabolic state and 
to reorganize depending on tissues energy requirements. 
Currently, understanding the impact of organelle morphological changes 
on the ATP production, or the role of fusion and fission of the mitochondrial 
network on control of oxidative phosphorylation represents an important 
challenge in bioenergetics: the discover that two hereditary neurodegenerative 
disorders such as autosomal dominant optic atrophy and Charcot-Marie-Tooth 
syndrome are associated to mutations in genes involved in the mitochondrial 
fusion regulation (OPA1 and MFN2) has further increased the interest in 
this field, revealing that the control of mitochondrial morphology may have 
a profound impact on cell physiology. The peculiar structure of mitochondria 
makes the fusion mechanism a singular issue: from in vivo studies in yeast the 
fusion of the outer and inner membrane appears temporally linked and also in 
human cells mitochondrial fusion implies a synchronous involvement of outer 
and inner membranes leading to matrix mixing; the question of how these 
two sets of compositionally distinct membranes are spatially and temporally 
coordinated and accurately fused is intriguing [141].
Changes in mitochondrial organization are associated to changes in cell 
physiological state: mitochondrial network fragmentation could occur 
synchronously with the cell cycle in human fibroblast [142] indicating that 
probably mitochondria need to dissociate to correctly segregate in the daughter 
cells or simply reflecting different energy requirements during mitotic steps. 
Mitochondria fragmentation is as well a crucial step in the apoptotic cascade; 
rearrangements in the membranes organization might be actually linked to 
cytochrome c release. The association between mitochondrial morphology 
and metabolism is supported by the large and tissue-dependent diversity in 
mitochondrial shape and organelles organization, with an important variability 
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of organellar section profile, intracellular localization and shape heterogeneity 
[4]. Differences between tissues concern also the number of cristae and 
the matrix density [143] further supporting the tight relationship between 
mitochondrial structure and function. 
As demonstrated in lymphocytes migration [144] redistribution of mitochondria 
in cytoplasm is accomplished as well by shape rearrangements. Indeed, 
nevertheless the mitochondrial network occupies a vast portion of cytosol the 
predominant location is near the nucleus or the plasma membrane but the 
relation with microtubules could permit to mitochondrial tubule to reorganize 
and accumulate in high-energy demanding cell areas [4]. Subcellular distribution 
of mitochondria could be relevant also to control the availability of oxygen that 
is differently is more or less, i.e. closer or further the plasmatic membrane. 
The dynamic of mitochondrial network is determined by the equilibrium 
resulting from the opposite action of fission and fusion, two processes that 
need to be carefully regulated to properly meet cell requirements. Proteins 
regulating mitochondrial morphology belong to a large group of conserved 
dynamin-related GTPase; the signature protein of this family, dynamin, plays 
an important role in endocytosis and synaptic vescicle recycling through 
membrane remodeling. The characterization of these processes in lower 
eukaryotes has allowed to identify the homologue proteins in mammalian and 
to hypothesize the probable mechanisms involved in the reorganization of 
mitochondrial network. 
In yeast, Dnm1 (dynamin 1) and Fis1 (fission 1) interact to induce fission 
[145] suggesting that also hFis1, the Fis1 homologue, might be implied in the 
human Drp1 (dynamin-related protein 1) recruitment on outer mitochondrial 
membrane. siRNA experiments have shown that Drp1 absence induce 
a decreased ATP synthesis and an essential increase in mitochondrial 
membranes fluidity [4] suggesting that also membrane structure is relevant in 
energy production. Interestingly, in yeast Dnm1 seems to localize in specific 
regions of mitochondrial outer membrane characterized by reduced diameter 
and corresponding to separation sites [146]; the proposed mechanism concern 
the formation of Dnm1 oligomers that wrap around the mitochondrial tubule 
leading to constriction and separation of mitochondria [147]. 
The study of mitochondrial dynamic has allowed to discover unexpected non-
apoptotic functions for Bcl-2 family members, revealing, as often occurs in 
biology, surprisingly connections between different pathways. Upon apoptotic 
signal Drp1 migrate from cytosol to mitochondrial membrane co-localizing with 
the proapoptotic proteins Bax and Bak, which are responsible for mitochondrial 
outer membrane permeabilization [148]. In C. elegans CED-9 (Bcl-xL homologue) 
interacts with Fzo1 (mitofusin homologue) promoting mitochondrial clustering 
and dramatic reorganization of mitochondrial networks [149] suggesting that 
anti- or proapoptotic proteins might as well act regulating the assembly of 
mitochondrial fusion/fission proteins. Several other papers have reported 
the relation between apoptosis and mitochondrial dynamic but it remains 
to be understood how the components of the fission and fusion machinery 
are functioning in coordination with members of the Bcl-2 family, although it 
can be inferred that modifications in mitochondrial membranes topology may 
control different pathways promoting or preventing the interaction  between 
transmembrane and intermembrane space proteins [148].
Besides apoptosis, mitochondrial morphology has been found to be also 
related to the motor proteins system. Efficient fission of mitochondria facilitates 
the transport of these organelles by anterograde motors: modulation of 
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dynein-dynactin system, involved in microtubules organization, impact on 
Drp1 localization promoting a more interconnected mitochondrial network 
and, consequently, a poorer anterograde transport [4]. Since mitochondria 
localization is fundamental particularly in neuronal cell, impairment in the 
equilibrium between fission and fusion leading to incorrect mitochondria 
distribution might have catastrophic consequences in high energy demanding 
nervous system sites as nodes of Ranvier.
In the context of mitochondrial pathologies mitochondrial dynamic might fit 
with the notions of threshold effect and complementation. The existence of 
a biochemical threshold indicates that there must be a minimal inhibition of 
a single oxphos complex to affect the overall oxidative phosphorylation: the 
existence of a threshold might be caused by the presence of an excess of 
inactive enzymes or reduced intermediates (cytochrome c and CoQ) stored in 
specific region and mobilized only if required. 
This hypothesis is supported by the apparently uneven proteins distribution 
between inner boundary membrane and cristae membrane as well as by the 
capability of these proteins to redistribute between these domains upon changes 
of the physiological state of the cell [150]. Moreover, it is probable that one of 
the primary function of fusion is to enable the exchange of contents between 
mitochondria: matrix fusion allow proteins exchange and, at a less extent, 
redistribution and eventually recombination of mtDNA molecules in nucleoids 
representing a possible way to rescue non-functional mitochondria.
On the other hand, fission could control the isolation of “old” or impaired 
mitochondria promoting their commitment to authophagy and/or have a role 
in the distribution of mitochondria in daughter cells during mitosis, becoming a 
very relevant phenomenon in presence of mutated mtDNA molecules.  
mitochondrial dysfunction in hereditary optic neuropathies
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1 Leber Hereditary Optic 
Neuropathy
LHON has been the first mitochondrial pathology to be associated to a point 
mutation in mtDNA [48]. The loss of bilateral vision, which represents the 
outcome of the pathology, is caused by optic nerve atrophy determined by 
specific degeneration of retinal ganglion cells with preservation of the other 
retinal structures. Genetically, LHON patients are characterized by mutations 
affecting mitochondrial genes encoding subunits of Complex I of the respiratory 
chain; several mutations have been identified in different LHON families but 
most of the reported clinical cases are linked to one of the three so called 
primary mutations: G3460A at ND1 gene, G11778A at ND4 gene and T14484C 
at ND6 gene. 
Although the first reported LHON case dates back to late 1800 and at present 
the pathology is well characterized from the histopathological point of view, 
the basic traits of this neuropathy are still poor understood. 
Unlike most of the pathogenic mtDNA mutations, the three LHON primary 
mutations are usually found in homoplasmic condition, i.e. each cell of every 
tissue contains only mutated mtDNA molecules. The homoplasmy represents 
one of the unresolved questions concerning LHON: currently, we do not know 
yet how a homoplasmic mutation presents in all tissues and affecting an 
ubiquitously expressed gene may result in the specific involvement of a single 
cellular type. 
LHON is a late-onset pathology, which first symptoms manifest after 20-25 life 
years. However, interestingly, the course is very short: in few months from the 
first signs complete blindness occur in both eyes, indicating simultaneous and 
bilateral degeneration of retinal ganglion cells.
Although homoplasmy is a common condition for LHON mutations not all carriers 
develop the pathology: the penetrance of LHON mutations is incomplete and 
highly variable also aong members of the same family members; moreover, 
LHON penetrance appears to be sex-linked: only 5-15% of women harboring 
a LHON mutation develop the pathology while in males the frequency reaches 
30-50% values [74]. 
The incomplete and sex-linked penetrance observed in LHON has driven the 
researchers to look forward putative genetic or environmental factors that 
might play a role in pathology modulation. The true involvement of X-linked 
loci still needs to be elucidated, while there could be a correlation with nuclear 
gene polymorphisms involved in oxidative stress or in apoptosis [73]; however, 
the effective role of these genetic traits in LHON pathogenesis has not yet 
been totally clarified. Mitochondrial DNA haplogroup J, containing polymorphic 
variants at ND1 and ND5 genes, seems to increase the penetrance in 
presence of G11778A and T14484C mutations [77], while no concordant data 
have been collected regarding the potential role of environmental factors. Few 
cases of vision rescue in LHON patients further increase the dark sides of this 
pathology.
Currently, the pathological mechanism leading to optic nerve atrophy in 
LHON is still unknown. The bioenergetic failure hypothesis has been tested 
in several cellular models leading often to discordant conclusions. The 
gene localization of LHON mutations necessarily predicts an involvement of 
oxidative phosphorylation but it is yet not clear how Complex I alterations can 
induce the neuropathy.  
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Optic nerve degeneration in LHON is due to a wave of apoptotic death that 
synchronously hits all RGCs: several reports have demonstrated that different 
LHON cellular model are more prone to apoptotic death with respect to control 
cells [110, 111, 113] indicating that programmed cell death is the final consequence 
of Complex I alterations deriving from the presence of primary mutations. 
Rising evidence suggests that a pivotal role in LHON pathogenesis is played 
by reactive oxygen species [113, 115, 116]. Oxidative stress is actually a common 
trait of different neurodegenerative diseases and the probability that optic 
nerve atrophy in LHON is the consequence of a complex interaction between 
energy failure, oxidative stress and apoptosis is very high.
The results reported in this dissertation derive from a project focused on 
the relative contribution of energy failure and oxidative stress in LHON 
pathogenesis: the potential role of the polymorphism of a nuclear gene (SOD2) 
involved in ROS production/scavenging has been analyzed in relation with the 
impact of one of the three primary mutations on the oxidative phosphorylation 
system.
SOD2
SOD2 is a nuclear gene encoding MnSOD (Manganese superoxide dismutase), 
a mitochondrial matrix enzyme catalyzing the dismutation of superoxide anion 
in hydrogen peroxide. The sequence and the genomic organization of SOD2 
gene show striking similarity among mouse, rat, bovine and human, indicating 
that its function has been well conserved during evolution. The absence of 
TATA and CCAAT boxes in the promoter and the presence of GC boxes suggest 
that SOD2 is a “housekeeping” gene [45], ubiquitously expressed. The human 
gene contains putative NF-kB transcription regulatory element located in the 
3′-flanking region of the gene [151]; in the promoter region of all four species are 
also present multiple copies of Sp-1 and Ap-2 consensus sequences. Sp-1 is 
a transcription factor with three zinc-fingers motifs essential for DNA-binding; 
its binding activity is impaired in vitro by hydrogen peroxide, thiol-modifying 
reagents and low levels of reduced glutathione (GSH) [32] indicating that the 
activity of this protein is regulated in response to modifications of the redox 
state of the cell. Ap-2 interacts with the 5′-flanking sequences of SOD2 gene: 
this transcription factor down-regulates the expression of human SOD2 gene 
via its interaction with Sp-1 within the promoter region [152]. Regulation of SOD2 
expression may also occur at translational level by the action of an mRNA-
binding protein whose activity is dependent on the cAMP phosphorylation 
cascade  [153].
After cytoplasm translation MnSOD monomers are imported into mitochondrial 
matrix where the enzyme is active as tetramer. Import of nuclear-encoded 
proteins is a complex process that requires the coordinated regulation of 
proteins active in the cytosol, in both mitochondrial membranes and in the 
matrix.
The targeting information of precursor proteins addressed to mitochondrial 
matrix resides in an amino-terminal sequence extension, the mitochondrial 
targeting sequence (MTS), which is cleaved out by a specific peptidase after 
import. The major characteristics of MTS are a high content of basic amino 
acids and amino acids with hydroxyl side chains, the virtual absence of acidic 
amino acids and the capability to form amphipathic helices in solution [154, 155]. 
Mitochondrial proteins encoded by nuclear genes cannot be translocated 
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across the mitochondrial membranes in a folded conformation; they must be 
in fact at least partially unfolded to fit the import channels. After crossing the 
outer membrane through the general import pore (TOM), imported proteins are 
directed to one of two translocases of the inner membrane (TIM21, TIM23). All 
proteins with a N-terminal MTS, including the matrix proteins, are directed to 
the TIM23 complex, which forms a channel across the membrane and allows 
to proteins to be driven into the matrix thanks to membrane potential. 
The import of nuclear-encoded proteins is then accomplished by an ATP-
dependent molecular system; the core protein of this system is represented by 
mitochondrial heat shock protein 70 (mtHsp70). The mitochondrial processing 
peptidase (MPP) terminates the process cleaving off the presequence, and 
the protein - assisted by folding helpers, such as Hsp70, Hsp60 or peptidyl-
prolyl cis/transisomerases - folds into its active form [156].
In human, MnSOD is targeted to mitochondria thanks to a N-terminal 24 
amino acids long sequence; as for other matrix proteins MnSOD monomers 
are imported trough the translocase of the outer membrane and the 
translocase of the inner membrane (TIM23) in a ΔΨ-dependent manner. Once 
in the mitochondrial matrix, the MTS is cleaved by mitochondrial processing 
peptidase and monomers are assembled in the active tetramer containing one 
manganese atom for each monomer [157]. 
MnSOD plays a critical role in the detoxification of mitochondrial superoxide 
anion and its activity is fundamental for cell life as demonstrated by knock out 
experiments. SOD2 homozygous mutant mice die within the first 10 days of 
life with a dilated cardiomyopathy, accumulation of lipid in liver and skeletal 
muscle, and metabolic acidosis [158]. According to Lebovitz et al. [159]SOD2 
knockout mice has been shown to survive up to 3 weeks of age but exhibiting 
several pathologic phenotypes including severe anemia, degeneration 
of neurons in the basal ganglia and brainstem, and progressive motor 
disturbances characterized by weakness, rapid fatigue, and circling behavior. 
These papers clearly provided evidence of the fundamental role played by 
MnSOD in cell physiology.
Ala16Val dimorphism 
In 1996 Shimoda-Matsubayashi reported a T to C substitution in -9 condon 
of the the SOD2 gene which changes the aminoacidid at position 16 in the 
mitochondrial targeting sequence from valine (GTT) to alanine (GCT) [160]. In 
the allele containing alanine the residues 10-17 are predicted to organize in 
an amphiphilic α-helix structure preceded by a β-sheet segment formed by 4-9 
residues. The substitution of the alanine with the valine would determine the 
disruption of the helix that would be substituted by a long stretch of β-sheet 
spanning through 4-20 residues. This report shows also that, in Japanese 
population, the allele containing alanine is more frequent in patients with 
Parkinson’s disease respect to control population.
The in vitro import of the human SOD2 alleles in rat mitochondria has been 
studied to evaluate the effect of MTS conformational change on protein function. 
The results obtained support the idea that the predicted conformational 
change modulates the import of MnSOD monomers into mitochondrial matrix. 
Probably because of its β-sheet conformation, the valine-containing variant is 
in fact characterized by a slower crossing of inner mitochondrial membrane 
with respect to the alanine-containing variant [157]. The authors proposed a two 
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steps model for the import of the valine-containing allele: the partial stalling in 
the inner membrane would retain the precursor in the intermembrane space 
for a longer time allowing its partial refolding. The necessity of unfolding the 
precursor in order to complete the import into the matrix slows down the 
entire process and it results in a minor efficiency of active homotetramer with 
respect to the alanine containing variant, as demonstrated by non-denaturing 
gel activity assay. 
Sutton and co-workers [161] has then studied the impact of SOD2 MTS 
dimorphism on mRNA stability in human cells transfected with both SOD2 
alleles. The data show that transfection of Ala-MnSOD allele leads to a four-
fold higher levels of the transfected active protein in the matrix with respect to 
the Val-MnSOD allele; moreover, the confirmed slower import of valine variant 
has been shown to be associated with a minor stability of the transcript in 
cytoplasm and with a higher proteasome-processing of the precursors. 
Since the great relevance of MnSOD function in cell physiology and, therefore, 
the necessity of a fine regulation of MnSOD activity, SOD2 dimorphism has 
been considered as a potential risk factor for different pathological states. 
The higher activity of SOD2 Ala variant has been associated with elevation 
of prostate cancer risk in Caucasians [162] and increased risk of breast cancer 
among Chinese women with high levels of oxidative stress or low intake 
of antioxidants [163]. Interaction between the SOD2 Ala/Ala genotype and 
environmental factors inducing oxidative stress in breast cancer risk has 
been also confirmed in American women [164] suggesting that an increased 
superoxide dismutase activity in mitochondria stressed by ROS exposure may 
further alter the redox balance of cell. In the same way, alcohol abusers with 
Ala homozygote phenotype show increased susceptibility to severe alcoholic 
liver disease [165], moreover, the presence of at least one Ala MnSOD allele 
increases the risk for developing cirrhosis in French alcoholics, the rates of 
hepatocellular carcinoma development and death in cirrhotic patients [166]. 
SOD2 dimorphism might as well be associated with development of type 2 
diabetes among Japanese-Americans, in this case the valine homozygotes 
would be exposed to a higher risk [167]. 
These and several other reports clearly indicate that either high or low 
superoxide dismutase activity in mitochondria, particularly in presence of 
stress input, might exacerbate latent pathologies. 
Interestingly, the study of SOD2 dimorphism has unearthed a link between 
MnSOD activity and iron metabolism.  Transfection with Ala-MnSOD in 
hepatoma cells has been shown to modulate the expression of several 
proteins involved in the uptake, extrusion, storage, and cellular distribution of 
hepatic iron, and lead to intracellular iron accumulation; accordingly, alcoholic 
cirrhotic patients with two Ala-MnSOD-encoding alleles frequently exhibit 
hepatic iron accumulation [168, 169]. An impaired regulation of iron metabolism 
could have detrimental effects increasing the risk of oxidative stress - see 
Fenton reaction - other than possibly interfere with the assembly of respiratory 
chain complexes, which function is highly dependent on Fe-S clusters. 
The demonstrated relevance of MnSOD dimorphism in several pathological 
conditions and the highly probable role of oxidative stress in LHON 
pathogenesis prompted us to consider the nuclear gene SOD2 as putative 
regulator of LHON mutations pathogenic potential.
Analyzing the distribution of SOD2 genotypes in an Italian cohort has shown that 
heterozygous genotype (AV) is more frequent in LHON patients than in control 
population, while the homozygous valine genotype shows the opposite trend 
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figure 1 
Distribution of SOD2 genotypes in an italian population cohort (sex matched).
figure 2 
Distribution of SOD2 genotypes in a brazilian LHON family.
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[fig.1]. The same analysis has been conducted on a large Brazilian pedigree 
characterized by the 11778/ND4 LHON mutation and by the mitochondrial 
J haplotype; according to the previous result, heterozygous genotype (AV) 
appears to be more frequent in LHON affected patients with respect to carriers 
[fig.2]. (Unpublished data kindly provided by Dr. Valerio Carelli).
The uneven distribution of SOD2 genotypes in LHON patients suggests that 
the SOD2 dimorphism might modulate the manifestation of LHON in subjects 
genetically predisposed. 
Supported by the results of population genetic analysis results we decided to 
investigate the relatioship between SOD2 genotypes (AA/AV/VV) and MnSOD 
content and activity in LHON patients harboring the 3460 ND1 LHON mutation 
as well as in a control population. Subsequently, the investigation has been 
carried on in order to elucidate if SOD2 can modulate the effect of Complex I 
LHON pathogenic mutations dysfunction on mitochondrial dysfunction. 
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Autosomal Dominant Optic 
Atrophy
ADOA, or Kjer’s disease, is a pathology associated to mutations in the nuclear 
gene OPA1. Although there is a remarkable difference in timing, with LHON 
being mainly acute and ADOA slowly progressive, the clinical endpoint of both 
optic neuropathy is identical. Also in this case patients manifest loss of central 
vision with selective and early involvement of the small, thinly myelinated 
fibers of papillo-macular bundle.  Besides the common specificity for retinal 
ganglion cells, LHON and ADOA share also the incomplete penetrance and 
the variability of clinical manifestation suggesting that also pathologies related 
to mitochondrial  protein encoded by nuclear gene might derive from the 
cooperation of different genetic/environmental elements. 
OPA1 gene encodes a dynamin-related protein showing GTPase activity. 
Alternative splicing and proteolytic cleavage determine the existence of several 
isoforms that potentially could have different functions and be differently tissue 
expressed. The final localization of Opa1 is the mitochondrial intermembrane 
space: the protein function is not yet well understood although modulation 
of OPA1 expression in yeasts and higher eukaryotes has shown that its 
activity is involved in mitochondrial fusion and in cristae remodeling. Several 
reports have shown the existence of multiple links between Opa1 activity and 
apoptosis: by a mechanism apparently independent on mitochondrial fusion 
Opa1 may regulate cytochrome c release from intermembrane space gaining 
a role also in the intrinsic apoptotic pathway and supporting the notion that 
nuclear-encoded proteins targeted to mitochondria work as active sensor in 
the crosstalk between these organelles and the rest of the cell. 
Particularly in neuronal cells mitochondrial network dynamic might have a 
profound impact on mitochondria distribution and energy supply because.
Since most of the OPA1 mutations associated to ADOA lies in the GTPase 
domain of the protein, haploinsufficiency is the more probable cause of Opa1 
dysfunction, although a dominant negative effect has been proposed for 
mutations lying in the oligomerization domain.
Fibroblasts grown in galactose medium with OPA1 mutations predicted to 
generate a truncated Opa1 protein have been reported to show impaired 
oxidative phosphorylation with mitochondrial fragmentation and increased 
susceptibility to apoptosis [140]. Moreover, the association of multiple mtDNA 
deletions with ‘ADOA plus’ phenotypes due to OPA1 missense mutations 
has suggested a putative role of OPA1 in mtDNA integrity maintenance 
[139]. However, the relative contribution of these alterations to “classical” 
ADOA pathogenesis as well as their mutual relationships has not yet been 
unraveled. Therefore, as LHON also ADOA is a peculiar model of selective 
neurodegeneration induced by mitochondrial dysfunction through a still 
unknown pathological mechanism.
In order to investigate the biochemical mechanisms leading to optic nerve 
atrophy and the cause-effect relationship between Opa1 dysfunction and 
energy production, we analyzed mitochondrial function and morphology 
in ADOA patients characterized by a novel mutation in the OPA1 GTPase 
domain. This project has been developed in collaboration with the research 
group of Prof. L. Vergani, University of Padova, Italy. 
The patients here reported are females belonging to the same family affected 
by prominent bilateral chronic progressive optic atrophy with childhood-onset. 
2
figure 3 
Opa1 in patient fibroblasts. Analysis of cDNA in ADOA fibroblasts shows four altered transcripts, resulting in 
three shorter mRNA (217, 211 and 160) and one longer (266) than normal allele (250), owing to cryptic splice 
encompassing exon 14 and/or intron 14. Sequence analysis indicated the produced proteins, schematically 
represented at the side.
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Two of them manifested also extraocular signs. In one case, the decrease in 
compound motor and sensory action potentials, a slightly reduced conduction 
velocity in the lower extremities and initial denervation signs at the tibialis 
anterioris bilaterally indicate a moderate-severe predominantly axonal 
sensory-motor peripheral neuropathy at the lower extremities. The second 
showed moderate muscle deficit at the right tibialis anterioris and winging 
scapulae. Electromyography disclosed mild decrease of motor and sensory 
conduction velocities in the lower extremities and increased distal latencies, 
indicating a predominantly demyelinating peripheral neuropathy at the lower 
extremities [170].
Complete sequencing of OPA1 demonstrated a new 38-base-pair deletion 
(c1410_1443+4del38) spanning exon and intron 14 in the catalytic GTPase 
domain, with a predicted splice-site defect [170].
Amplification of cDNA extracted from patient fibroblasts revealed the presence 
of five different transcripts, one produced by the wild-type allele, the others 
resulting from the activation of cryptic splice sites in exon 14 or intron 14. The 
most abundant transcript encodes a truncated protein through the presence 
of an in-frame UAA termination signal in the retained intronic sequence, 11 
codons after the deletion breakpoint, with a predicted protein product of 481 
amino acids. The three shorter transcripts, which are much less abundant and 
maintain the correct reading frame, are predicted to produce proteins lacking 
11, 13 or 30 amino acids within the GTPase domain. It is not clear if these 
polypeptides are stable; however, it should be noted that the longest transcript 
accounts for the vast majority of aberrant transcripts in patient fibroblasts 
(>75% on densitometric analysis). Consistent with the molecular data is the 
reduced abundance of full-length Opa1 protein in patient fibroblasts obtained 
by immunoblotting (47% of controls) [170]. [fig. 3]
The interest in the OPA1 mutations derives not only from the several merging 
features shared by ADOA and LHON but also by the emerging necessity of a 
careful study of a relatively new aspect of mitochondrial function: the ability to 
fuse or fission possibly in response to particular metabolic requirements. 
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Protection of cells with energy 
deficiency
Whatever is the genetic defect, mitochondrial pathologies usually share 
the common features of a defect in the oxidative phosphorylation system 
that can lead to a mild or severe reduction of ATP synthesis, resulting in 
a possibly insufficient energy supply for the cell. In order to overcome the 
energy deficiency created by oxphos complex deficiency, respiratory chain 
substrates (CoQ, ascorbate, NADH or FADH2 precursors) supplementation 
has been tested in patients with defects of oxphos system. Unfortunately, 
up today results from different tests have not been so promising and more 
extensive trials are necessary in order to clarify the real efficacy of this kind 
of treatments.
Although it has not been extensively analyzed in humans, experimental works 
in animal cells exposed to hypoxia/reoxygenation cycles and mutant yeast 
have shown that an increased substrate-level phosphorylation could generate 
enough ATP to correct energy defects caused by different mechanisms [171, 
172]. 
These results suggest that “forcing” substrate-level phosphorylation to work 
overtime may be a viable approach to remedy the energy crisis due to oxphos 
impairment. The reported data in these papers bode well for application to 
patients. To optimize this strategy to human cells, we have chosen exogenous 
substrates possibly capable of stimulating the Krebs cycle flux and at the same 
time of removing the excess of reduced pyridine nucleotides (NADH) in oxphos-
deficient cells. In Krebs cycle α-ketoglutarate is converted by α-ketoglutarate 
dehydrogenase in succinyl-CoA with concomitant reduction of NAD; succinyl-
CoA is then converted in succinate by succinyl-CoA synthetase (A-SCS): the 
reaction results in the formation of an high energy phosphate bond in form of 
ATP or GTP that can be transferred by the nucleoside-diphosphate kinase to 
one ADP molecule to give ATP. The aspartate is added as indirect source of 
NAD in order to allow to α-ketoglutarate dehydrogenase to keep working.
To verify the validity of this approach in human cells in vitro, we have used both 
experimental models (in which cells are “poisoned” with a specific inhibitor) 
and “natural” models (cybrids harboring pathogenic mutations).
As experimental model we chose resting fibroblasts because the most severely 
affected tissues in mitochondrial diseases are slowly proliferating post-
mitotic tissues, such as brain and muscle. Carrying out experiments under 
conditions of high-energy demand in resting fibroblasts better approximates 
the vulnerability of post-mitotic tissues to mitochondrial dysfunction.
To achieve the condition of impaired energy production in high-energy demand 
cells we added gramicidin and oligomycin to the culture medium of resting 
fibroblasts. Gramicidin is an ionophore capable to increase the membrane 
permeability to monovalent cations: the cell is supposed to respond to 
gramicidin by increasing the ATP consumption in order to maintain the Na+/
K+ plasmembrane gradient. Oligomycin specifically binds to the Fo domain 
of the ATP synthase; the presence of oligomycin inhibits ATP synthase by 
blocking the proton translocation. Therefore, oligomycin reduces cell capacity 
of producing energy by oxidative phosphorylation hypothetically miming the 
effect of mutated subunits in the complex.  
The “natural” model is represented by cybrids carrying T8993G or T8993C 
mutations in the mitochondrial gene encoding the ATPase 6 subunit of ATP 
3
46
synthase. These mutations are associated with NARP or with the more severe 
MILS (Maternally Inherited Leigh Syndrome) depending on the mutation load, 
although the T8993C causes milder clinical phenotypes. Clinical features 
of NARP may variably include peripheral neuropathy, retinitis pigmentosa, 
cerebellar atrophy, mental retardation, and less frequently epileptic seizures, 
cardiomyopathy, deafness and optic atrophy. MILS is dramatically characterized 
by bilateral subacute lesions of the basal ganglia, which extending to the 
brainstem lead to death of the patient. As previously reported [53], the different 
severity of T8993G and T8993C mutations is linked to the different effect on 
mitochondrial metabolism. Both mutations lead to energy deprivation and ROS 
overproduction however, the relative contribution and the severity of the two 
pathogenic components is different depending on the mutation considered. 
The T8993G change mainly induces a dramatic energy deficiency, whereas 
the T8993C mutation favors a significantly increase of ROS production.
The supplementation of α-ketoglutarate and aspartate has been tested also 
in cybrids harboring the A8344G mutation affecting the mitochondrial gene 
encoding the tRNALys. This mutation is associated to MERRF, a form of 
Myoclonic Epilepsy with Ragged Red Fibers in which the tRNALys mutation 
alters the translation of mtDNA encoded genes.
The effect of metabolites sustaining substrate-level phosphorylation in resting 
fibroblasts and in NARP and MERRF cybrids has been tested in a glucose-free 
growth medium where the carbon source has been substituted by galactose: in 
this condition the cells are forced to use oxidative phosphorylation to produce 
energy because the slow metabolism of galactose to glucose-1-phosphate 
does not allow to satisfy the cellular energy demand by glicolysis. Cell viability 
and ATP content have been considered as parameters to assay the capability of 
exogenous substrate to rescue energy failure in view of a potential alternative 
pharmacological treatment for mitochondrial pathologies.
mitochondrial dysfunction in hereditary optic neuropathies
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1 Leber Hereditary Optic 
Neuropathy
Nevertheless LHON is a long time known pathology, the molecular mechanism 
that links mutations in Complex I subunits to optic nerve atrophy is still not 
understood. The energy failure hypothesis has been tested in several cellular 
models and the results obtained are greatly variable depending on the used 
experimental model. In our laboratory it has been shown that in LHON cybrids, 
homoplasmic for either one of primary mutations, the rate of ATP synthesis 
measured in the presence of nicotinamide adenine dinucleotide (NAD)–
dependent substrates was strongly reduced, with the 11778/ND4 mutation 
having the milder effect. These results were also confirmed by polarographic 
experiments. However the measurement of cell ATP content did not show 
any difference between LHON and wild type cybrids, suggesting that LHON 
cybrids may compensate the mitochondrial defect with glycolysis [105]. 
In this study we focused on the probable role played by the nuclear gene SOD2 
in the modulation of LHON pathogenesis. We tested the relationship between 
the Ala16Val dimorphism in the mitochondrial targeting sequence of SOD2 
gene and the oxphos efficiency to verify if a particular SOD2 genotype could 
modulate the effect of the 3460/ND1 LHON mutation on cell dysfunction.
In the present work, the impact of the 3460/ND1 mutation on the oxidative 
phosphorylation system and the putative role of MnSOD gene polymorphism 
in the incomplete and variable penetrance of LHON disease  has been 
evaluated in primary human cells of  patients. 
Controls and patients have been recruited by Dr. Valerio Carelli’s laboratory 
at Neurological Department of Bologna University where genotype 
characterization - for both LHON and SOD2 variants - has been carried out.
Effect of SOD2 dimorphism on MnSOD activity and 
content in human platelet enriched fraction 
The effect of mitochondrial targeting sequence dimorphism in SOD2 gene has 
been investigated analyzing the MnSOD activity and its mitochondrial content 
in a control group composed by 24 individuals as reported in the materials and 
method section. Previously analysis of this SOD2 dimorphism has shown that 
in mitochondria and cells transfected with Ala and Val alleles the dimorphism 
is associated with a different import efficiency resulting in a different content 
of active enzyme in mitochondrial matrix. The presence of a valine residue in 
the 16 position of the MTS determines a lower stability of the transcript and 
a β-sheet conformation of the precursor protein; the consequence of these 
variations is a slower import of monomers associated to a lower superoxide 
dismutase activity [157, 161]. 
In the control group, for each individual, the superoxide activity has been 
measured in the soluble fraction  obtained from HPBF (leukocytes and 
platelets) while the MnSOD content has been determined by western blot in 
the mitochondrial fraction extracted from the same cell preparation.  
As shown in Fig.1 our results are  in agreement with that obtained in transfected 
systems. Samples deriving from individuals with SOD2 heterozygous genotype 
are characterized by a significantly higher MnSOD activity with respect to both 
Ala homozygotes (-43%, p  < 0.05)  and Val homozygotes (-70%, p < 0.01). 
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figure 1 
MnSOD activity in HPBF of controls with  either one of three SOD2 genotypes. 
Because the enzyme is active in the mitochondrial matrix, activity values were normalized by citrate synthase 
to take account of the mitochondrial mass in different cells.
figure 2 
CuZnSOD activity. 
The enzymatic activity in HPBF of controls with  either one of three SOD2 genotypes is calculated on difference 
between the total superoxide dismutase activity and MnSOD activity.
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The enzyme activity, that is  expressed as units per mg of cellular protein (U/
mg), has been determined considering  the protein quantity capable to induce 
50% inhibition of  the NBT (Nitroblue Tetrazolium) reduction rate as “MnSOD 
activity unit”. Moreover the activity values have been normalized  to citrate 
synthase activity, that is an index of mitochondrial mass, in order to prevent 
errors due to the possibly different purity of analyzed samples. 
The CuZnSOD activity, calculated on difference between the total superoxide 
dismutase activity and the MnSOD activity, does not result significantly different 
among the three control groups, suggesting the absence of “compensatory” 
effect involving SOD1 product [fig.2]. 
Concomitantly, we evaluated the mitochondrial content of MnSOD to assess 
if the higher MnSOD activity was actually determined by a different import of 
monomers into the mitochondrial matrix. MnSOD protein was quantified in 
mitochondria isolated from control cells by SDS-PAGE and Western blot followed 
by immunodetection. The amount of MnSOD protein band has been determined 
and expressed as percentage of the mitochondrial pyruvate dehydrogenase 
complex E1α subunit-band, that has been used as protein standard. As shown in 
fig.3 the percentage of MnSOD monomer was found to be about 72 %, 85% and 51 
% in control samples carrying the AA, AV and VV MnSOD genotype, respectively. 
More the amount of MnSOD monomer detected in heterozygous samples was 
statistically higher with respect to both SOD2 homozygous genotypes samples 
(p < 0.05 vs Ala homozygotes and p < 0.01 vs Val homozygotes); in this case 
the observed differences result statistically significant also between the two 
homozygous genotypes groups (p < 0.01). 
The ratio between the amount of MTS-MnSOD (26 KDa) and MnSOD (23 
KDa) monomer was quantified in the soluble fraction obtained from sonicated 
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figure 3 
MnSOD content in  HPBF of controls with  either one of three SOD2 genotypes.
a) MnSOD protein is expressed as the percentage ratio between densitometric values of MnSOD and E1α, 
considered as internal control. 
b) Chemoluminescent spots of MnSOD monomers and E1α subunits in three SOD2 genotypes.
figure 4 
MTS - MnSOD content.
a) Ratio between unprocessed and mature MnSOD in whole cell of controls with different SOD2 genotypes. b) 
After the proteolytic cleavage in the mitochondrial matrix the monomer shows a molecular weight of 23 KDa. 
The unprocessed protein, still containing the mitochondrial targeting sequence, shows a molecular weight of 
26 KDa. Tubulin was used as internal control. 
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controls by SDS-PAGE (using a 16-19% polyacrilamide gradient) and 
western blot [fig.4a]. By densitometric analysis the percentage mean value 
of the targeted mitochondrial protein was about 18%, 42% and 68% in the 
protein samples extracted from cells carrying AA, AV, VV MnSOD genotype, 
respectively [fig 4b]. According to previous published data [157, 161], our results 
indicate that the Val-containing monomers, retained for a long time in the 
cytoplasm, are less efficiently imported into the mitochondrial matrix and then 
assembled into active enzyme.  
Our results clearly show that the SOD2 dimorphism affecting the mitochondrial 
targeting sequence  can modulate the MnSOD activity of controls being 
the highest MnSOD activity of heterozygotes well related with the MnSOD 
monomer protein content in mitochondrial matrix. Interestingly, as shown by 
statistical analysis of the SOD2 genotypes, the presence of both MTS-MnSOD 
alleles (AV genotype) seems increase the probability of developing LHON in 
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figure 6 
MnSOD activity.
MnSOD activity in control (purple) and 3460/ND1 LHON (white) lymphocytes in different SOD2 genotypes. As 
previously reported, activity values were normalized by citrate synthase to take account of the mitochondrial 
mass in different cells.
figure 5 
Correlation graph. 
In the graph the MnSOD quantity and activity’ average values of the control group are represented.
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individuals harboring a LHON primary mutation.
Indeed, our results shows that the highest MnSOD activity observed in 
heterozygotes is strictly and actually associated with the content of active 
enzyme in mitochondria. In the correlation graph [fig. 5] are reported the 
MnSOD activity and quantity average values determined in the three control 
groups carrying different SOD2 genotypes.  
Effect of SOD2 dimorphism on MnSOD activity 
and content of controls and LHON patients 
lymphocytes
Supported by the results obtained in the control population group we decided to 
analyze the effect of SOD2 gene polymorphism in LHON patients lymphocytes 
(twelve individuals total) harboring the 3460/ND1 mutation.  The results 
obtained measuring the MnSOD enzyme activity are in agreement with what 
we have previously observed in the controls population and it might support 
the hypothesis that SOD2 dimorphism plays a role in modulation of LHON 
penetrance. In fig. 6 it is reported the MnSOD activity normalized on citrate 
synthase activity (Units/CS), measured in different experimental groups. In 
controls as well in LHON patients SOD2 heterozygous genotype is associated 
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figure 7 
MnSOD content.
a) MnSOD content in 3460/ND1 LHON lymphocytes with  either one of SOD2 genotypes. Reported values 
derive from the ratio between MnSOD and E1α quantity, considered as internal control. 
b) Chemiluminescent spots of MnSOD monomers and E1α subunits in three SOD2 genotypes of LHON 
lymphocytes.
figure 8 
CuZnSOD activity.
CuZnSOD activity in control (purple) and 3460/ND1 LHON (white) lymphocytes in different SOD2 genotypes.
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with the highest activity of MnSOD. In the control group the enzyme activity 
differences (AV 0.61 ± 0.07 Units/CS, AA 0.49 ± 0.16 Units/CS, VV 0.42 ± 0.01 
Units/CS) result statistically significant only between heterozygotes and valine 
homozygotes (p< 0.01). Interestingly, in LHON patients the presence of the 
Ala allele in both heterozygous and homozygous combination is associated 
with an increase of MnSOD activity with respect to controls. However, the 
statistical significance is reached only comparing the enzyme activity of LHON 
heterozygotes vs the one of control heterozygotes (p < 0.01). Also in LHON 
lymphocytes protein quantification by western blot has confirmed an increase 
of the MnSOD content in patients carrying  both SOD2 gene alleles [fig. 7]. 
As expected, the high superoxide dismutase activity observed in SOD2 
heterozygotes seems to be a peculiar feature of  MnSOD: indeed CuZnSOD 
activity does not seem to be affected by SOD2 genotype and it does not show 
significant differences between LHON patients and controls [fig. 8]. 
The evaluation of catalase activity has been carried out in order to assess if 
SOD2 genotypes are associated with “reorganization” of antioxidant enzyme 
systems other than the MnSOD. As well as for CuZnSOD activity, also catalase 
activity does not vary between different groups [fig. 9], suggesting that the 
increased MnSOD activity observed in SOD2 heterozygotes is not associated 
with a parallel increase of other antioxidant enzyme activities.
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figure 10
Complex I-driven ATP synthesis rate.
ATP synthesis rate in presence of NADH-dependent substrates in control (purple) and LHON (white) 
lymphocytes. Values were normalized by citrate synthase activity considered as index of mitochondrial mass.
figure 9 
Catalase activity. 
Catalase activity in control (purple) and 3460/ND1 LHON (white) lymphocytes in different SOD2 genotypes. 
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ATP synthesis rate in lymphocytes from controls 
and LHON patients
Mitochondrial function has been evaluated in lymphocytes isolated from 
peripheral blood of LHON patients and controls. The ATP synthesis rate has 
been considered as reliable parameter for testing the effect of 3460/ND1 LHON 
mutations on oxphos, it means on cellular energetic capability.  Controls and 
LHON patients lymphocytes data were matched depending on SOD2 genotype 
in order to highlight the potential association between the mitochondrial 
MnSOD activity and the pathogenic power of mutation. We measured either 
the Complex I-driven ATP synthesis in the presence of malonate, an inhibitor of 
succinate dehydrogenase complex, or the Complex II-driven ATP synthesis in 
the presence of rotenone, a specific NADH dehydrogenase complex inhibitor. 
After inducing the in vitro ATP synthesis for 3 minutes, ATP extracted from 
samples was quantified with a chemiluminescent method based on luciferin-
luciferase reaction using a known amount of ATP as standard.
As shown in fig.10 independently of the SOD2 genotype lymphocytes deriving 
from LHON patients are characterized by a reduced capability to synthesize 
ATP in presence of Complex I substrates (p < 0.01). The extent of reduction 
- 45% in Ala homozygotes (AA), 39% in heterozygotes (AV), 46% in Val 
homozygotes (VV) - suggests that the effect of LHON pathogenic mutations 
on oxphos function could be not significantly dependent on SOD2 genotype. 
The evaluation of Complex II-driven ATP synthesis has confirmed the 
exclusive impairment of Complex I function in LHON patient cells: there are 
no significant differences between the succinate-driven ATP synthesis rate of 
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figure 12 
Citrate synthase activity. 
Citrate synthase activity in control (purple) and LHON (white) lymphocytes.
figure 11
Complex II-driven ATP synthesis rate.
ATP synthesis rate in presence of succinate in control (purple) and LHON (white) lymphocytes. Values are 
normalized by citrate synthase activity considered as index of mitochondrial mass.
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LHON patients and controls lymphocytes and it does not result affected by 
SOD2 genotypes [fig. 11]. 
The ATP synthesis rate values have been reported after normalization to 
citrate synthase activity of each analyzed sample. Although there are no 
significant differences between LHON patients and controls, lymphocytes of 
both Ala homozygotes and heterozygotes show a trend toward an increased 
citrate synthase activity with respect to SOD2 genotype matched controls 
[Fig. 12]. Because of the citrate synthase activity results we hypothesized 
that in LHON patients the presence of an Ala allele in the SOD2 mitochondrial 
targeting sequence could be associated with an increased mitochondrial 
content. To address this hypothesis the mtDNA copies number of controls 
and LHON patients lymphocytes has been determined. Although a trend 
toward an increased mtDNA copies number is observed in Ala homozygotes, 
in the control group the presence of different SOD2 genotypes does not 
significantly affect the number of mtDNA molecules. Interestingly, only in 
LHON patients the presence of at least one Ala allele in the SOD2 gene, i.e. 
in both homozygosis and heterozygosis, is associated with a significant higher 
quantity of mitochondrial DNA with respect to Val homozygotes [fig.13]. 
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figure 13 
Mitochondrial DNA copy number.
Mitochondrial DNA copy number in control lymphocytes (a)  and in 3460/ND1 LHON lymphocytes (b). 
While in control population the presence of different SOD2 genotypes does not affect the number of mtDNA 
molecules, LHON patients with at least one Ala allele show an increased number of mtDNA molecules respect 
to valine homozygotes.
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Discussion
MnSOD is the main antioxidant enzyme that scavenges superoxide and 
could be considered the first line of defense against O2•- generated in the 
mitochondrial matrix by electron transport chain. In mice, complete ablation 
of MnSOD causes early postnatal death with severe oxidative damage to 
mitochondria and increased sensitivity to hyperoxia [158,159]. The study of the 
SOD2 Ala16Val dimorphism has demonstrated that MnSOD genetic variants 
represent a risk factor for different kind of pathologies. The presence of Ala 
allele seems to increase the risk of cancer and liver diseases in predisposed 
subjects [162,163,164], while the Val allele in homozygosis increases the risk for type 
2 diabetes [167]. Indeed, it is clear that MnSOD activity need to be excellently 
regulated in order to maintain cell redox equilibrium: surprisingly, in presence 
of preexisting stress factors, even a too high superoxide dismutase activity in 
mitochondria could be deleterious for cell physiology [164, 165].
The variable penetrance of LHON disease and the notion that, besides energy 
failure, oxidative stress plays a pivotal role in LHON pathogenesis have 
prompted us to study the frequency of SOD2 genotypes in order to verify if the 
MTS variants are evenly distributed in LHON cohorts and in control population. 
As reported in the previous section, either comparing LHON versus controls 
or, in the same LHON family, affected individuals versus carriers the SOD2 
heterozygous genotype (AV) seems increase the probability of manifesting the 
pathology. These results prompted us to study the effect of SOD2 dimorphism 
on MnSOD activity in order to investigate the molecular mechanism by which 
SOD2 genotype could eventually modulate the pathogenic potential of LHON 
mutations. 
The results obtained show that, as hypothesized, the Ala16Val dimorphism in the 
MTS of MnSOD monomer is linked to a different import efficiency of the protein: 
in a control population the presence of the Ala allele in the SOD2 genotype 
determines a higher mitochondrial content of MnSOD monomer with respect to 
controls carrying the VV SOD2 genotype; moreover it results in an increased 
MnSOD enzyme activity. Interestingly, the highest MnSOD quantity and activity 
are found in controls harboring the heterozygous SOD2 genotype. 
The same trend is also found in patients harboring the 3460/ND1 LHON 
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mutation but in LHON with SOD2 heterozygous genotype the MnSOD activity 
is significantly higher than in SOD2 genotype matched controls. 
Concerning the bioenergetic defect, we demonstrated that in lymphocytes the 
3460/ND1 LHON mutation induces alterations in Complex I catalytic activity 
that determine  a reduction of cell capability to synthesize ATP through the 
oxidative phosphorylation. Moreover, as demonstrated by measurements of 
the Complex II driven ATP synthesis rate, the energy failure of LHON patient 
cells is strictly and only dependent on Complex I dysfunction. 
The extent of the ATP-synthesis rate reduction detected in LHON lymphocytes 
is independent on patients SOD2 genotypes, i.e. none of the MnSOD allele 
is capable to mitigate or exacerbate the effect of LHON mutation on the 
mitochondrial energy metabolism. Thus, the modulation of LHON mutation 
pathogenicity by MnSOD might occur through mechanisms that do not directly 
involve Complex I and oxidative phosphorylation impairment.  
Our data further support the theory regarding the impact of Ala16Val 
dimorphism on the peptide secondary organization: the presence of a valine 
determines a β-sheet conformation of the SOD2 mitochondrial targeting 
sequence that induces a partial stall of the monomer during its translocation 
into mitochondria [157,160] determining a minor content  of the valine-containing 
peptide in the matrix. Interestingly, the MnSOD variants have a different 
behavior not only during the import process: the slowly imported Val variant is 
actually more prone to proteasomal degradation and its mRNA shows a minor 
stability, possibly due to impaired cotranslational import [161].
Based on this evidence, it can be inferred that SOD2 variants could as well 
being differently regulated at transcriptional level: the valine allele, showing 
poor import efficiency, could determine an up-regulation of SOD2 expression. In 
case of heterozygosity the up-regulation would have the major effect because 
the overexpressed alanine allele would easily reach the mitochondrial matrix 
causing an accumulation of monomers and, thus, of active enzyme. If two 
valine alleles were present, the up-regulation would have no effect because of 
the instability of monomers and mRNA in cytoplasm and because of the partial 
stall during the inner mitochondrial membrane crossing.
The different regulation of MnSOD expression in individuals carrying different 
MnSOD2 genotypes would explain why we found a higher quantity and activity 
of MnSOD in heterozygotes with respect to both AA and VV homozygotes. 
The higher superoxide activity is specifically due to the SOD2 gene product as 
demonstrated by the absence of differences in the CuZnSOD activity between 
our experimental groups. 
In order to verify if the different MnSOD activity affects expression and/or 
regulation of other antioxidant enzymes we have measured the activity of 
catalase, which acts as hydrogen peroxide scavenger. Interestingly, catalase 
function seems not dependent on SOD2 genotype: indeed all samples tested 
show a very similar enzymatic activity. 
As previously reported, MnSOD catalyzes the dismutation of anion superoxide in 
mitochondrial matrix. The reaction involves the oscillation of Mn oxidation state 
and the formation of one molecule of hydrogen peroxide from two superoxide 
anion molecules. Although superoxide anion radical spontaneously dismutes 
to O2 and H2O2 quite rapidly, superoxide dismutase activity is biologically 
necessary because superoxide reacts even faster with NO radical to form 
peroxynitrite, a very powerful oxidant. To counteract the accumulation of this 
toxic molecule the cell has then evolved an efficient system, whose reaction 
rate is limited only by diffusion. Besides the powerful action of MnSOD as O2•- 
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scavenger, it must to keep in mind that the product of its catalytic process is a 
non-radical molecule that belongs to reactive oxygen species and that could 
have a toxic effect. Hydrogen peroxide, other than working as messenger 
in signal transduction pathways at low concentration, can in fact irreversibly 
modify proteins or react with iron to give hydroxyl radical, a highly reactive 
oxidant molecule capable to induce modifications also in DNA. Thus, the 
activity of MnSOD needs to be finely regulated in order to maintain the correct 
balance between superoxide anion and hydrogen peroxide concentrations in 
mitochondria.
Based on our results, it can be suggested that, in absence of increased 
hydrogen peroxide scavenging capacity, in SOD2 heterozygotes the high 
MnSOD activity might determine an increase of the hydrogen peroxide cellular 
content. 
A steady state characterized by a higher concentration of hydrogen peroxide 
could explain the possible effect of SOD2 heterozygous genotype in LHON 
pathogenesis: an unbalance of the hydrogen peroxide production and 
scavenging determined by the increased MnSOD activity, in the absence 
of compensatory mechanisms, could create a more sensible mitochondrial 
environment to the effect of LHON mutations. The reduction of Complex I 
activity in a context of increased oxidative stress, although not necessarily 
leading to energy failure in the whole cell [105], could anyway have deleterious 
effect on the regulation of the overall mitochondrial function that, particularly in 
neuronal cells, must be finely controlled to readily reply to different requirements 
in terms of energy metabolism, calcium buffering, apoptotic commitment and 
mitochondria localization along the different axons regions. The increased 
content of mtDNA in LHON patients characterized by at least one Ala allele 
of SOD2 gene confirms that there must be some tight link between MnSOD 
activity and pathogenic effect of LHON mutations. The prominent effect of 
oxidative stress could contribute to explain the gender bias observed in 
LHON: women could be less prone to develop the pathology because of 
estrogens that, particularly in retinal tissue, could have a protective function. 
Bovine and rat retinas have been shown to express both estrogen receptor 
isoforms (ERα and ERβ) throughout the retinal thickness but particularly in 
the ganglion cell layer, and also in humans ERβ protein has been localized 
in the ganglion cell layer [117, 173]. Other than as signals molecules - acting 
stimulating the expression of antioxidant enzymes - estrogens can achieve a 
neuroprotective function working directly as potent antioxidants by quenching 
free radicals and terminating their propagation [117, 173]. Moreover, 17β-estradiol 
has been shown to be involved in brain metabolism regulation stimulating 
glucose import and catabolism through an increased expression of glycolytic 
enzymes and pyruvate dehydrogenase subunits [174]. Furthermore, 17β-
estradiol may as well regulate mitochondrial metabolism stimulating Complex 
IV subunits expression resulting in an enhancement of energetic efficiency [174]. 
The double effect of estrogens in oxidative stress protection and energy 
metabolism stimulation might represent a discriminating factors contributing 
to the increased penetrance of LHON in males.
58
Autosomal Dominant Optic 
Atrophy
Although the relationship between mitochondrial morphology and function 
has not yet been elucidated, evidence shows that defects in mitochondrial 
morphology could be associated with alteration of the energy production 
system. To better understand this relationship we have studied, in collaboration 
with Professor Lodovica Vergani of Padova University, the mitochondrial 
function in fibroblasts isolated from patients carrying a novel mutation in the 
OPA1 gene. The mutation generates a truncated form of Opa1 protein and 
is associated with a particular ADOA phenotype, characterized by muscular 
atrophy and optic nerve degeneration. Skeletal muscle biopsies analysis has 
shown the presence of subsarcolemmal and intermyofibrillar aggregates of 
mitochondria with increased size variability and focal cristae abnormalities 
suggesting that the mutation deeply affect mitochondrial morphology. On the 
contrary, unlike reported for a different OPA1 mutation [139], the mitochondrial 
DNA content was similar in ADOA compared to controls. Mitochondrial 
morphology has been further studied through confocal microscopy analysis in 
fibroblasts and in myotubes differentiated from myoblast isolated from muscular 
biopsy. The use of mitochondria targeted red fluorescent protein (mtRFP) has 
shown that a significant proportion of OPA1-mutated fibroblasts presented 
fragmented mitochondria, appearing as spheres or very short rods compared 
to interconnected tubules seen in control fibroblasts. Aberrant mitochondrial 
shape has been observed also in differentiated myotubes that showed a tubular 
mitochondrial network alternated with areas of fragmented mitochondria, even 
in the same cell. Moreover, spatial distribution of mitochondria was irregular in 
ADOA myotubes with areas of abnormal mitochondrial clustering while other 
areas were almost completely devoid of mitochondria [170].
To verify whether the observed organelle shape changes were a primary 
consequence of OPA1 pro-fusion activity loss, we performed a mitochondrial 
functional analysis in fibroblasts isolated from two ADOA patients [170], in order 
to verify if energy failure could contribute to the pathogenic mechanism that 
cause the optic nerve degeneration associated to Opa1 mutant form.
ATP synthesis rate
To study the role of OPA1 mutation on mitochondrial function we measured 
the ATP synthesis rate driven by Complex I in resting fibroblasts grown under 
different metabolic conditions. Besides the standard growth medium containing 
glucose [fig.14a] we tested the oxphos efficiency substituting glucose 
with galactose, in presence of pyruvate, to force cells to rely on oxidative 
phosphorylation for energy production. Galactose induces a down regulation 
of the glycolytic pathway because it is very slowly converted to glucose-6-
phosphate [fig.14b]. In this experimental condition the presence of gramicidin 
further stress the mitochondrial metabolism: indeed, this ionophore forms 
selective cations channels inducing a higher energy-demand to maintain cell 
homeostasis activating the plasma membrane Na+/K+ ATPase [fig.14c]. 
Although in all culture conditions no statistically significant differences have 
been found between ADOA and controls fibroblasts, our results indicate that 
the higher is the energy produced by oxphos, the lower is the ATP synthesis 
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figure 14
Complex I-driven ATP synthesis rate.
Complex I-driven ATP synthesis rate measured in fibroblasts of both controls and ADOA patients cultured in 
25 mM glucose-110 mg/l pyruvate medium (a), 5 mM galactose-110 mg/l pyruvate medium (b) and 5 mM 
galactose-110 mg/l pyruvate+40 ng/ml gramicidin medium (c).
figure 15
ATP content.
ATP content in fibroblasts of both controls and 
ADOA patients cultured in 5 mM galactose-
110 mg/l pyruvate medium for 72h.
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rate in ADOA compared to controls. As 
shown in fig.15 the slight difference 
observed in ATP synthesis rate in 
fibroblasts grown in galactose medium 
does not determine decreased energy 
availability in ADOA fibroblasts that 
show a similar ATP content compared 
to controls.
 
Mitochondrial membrane potential 
Dysfunctions of both mitochondrial respiratory chain and ATP synthase, 
and integrity of the inner mitochondrial membrane  were also investigated 
in both state 3 and 4 respirations using rhodamine-123. The mitochondrial 
membrane potential (ΔΨ) was measured by the fluorescence quenching of 
the potentiometric probe. In galactose/pyruvate medium ADOA cells show a 
slightly increased ΔΨ that is not statistically significant either during active 
oxidative phosphorylation (state 3) or when the ATP synthase is inhibited by 
oligomycin (state 4) [fig. 16 a,b].
Moreover the mitochondrial membrane potential in different respiratory 
conditions has been evaluated with TMRM using fluorescence microscopy. 
Confirming the results obtained with the spectroflourimetric method, no 
significant difference between controls [fig. 17 a, b] and patients [fig. 17 a1, 
b1] was observed in any tested culture condition. 
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figure 16 
Mitochondrial membrane potential.
RH-123 steady-state fluorescence quenching (F.Q.) mean values measured in galactose-grown fibroblasts of 
both controls and ADOA patients under state 3 (a) and 4 (b) respiratory conditions.
figure 17 
Mitochondrial membrane potential. 
Images of fluorescence microscopy of control and ADOA  fibroblasts maintained in galactose/pyruvate 
medium. Mitochondrial membrane potential was measured by means of TMRM probe under different 
metabolic state. State 3 of respiration: a) control , a1) ADOA fibroblasts. State 4 of respiration b) control, b1) 
ADOA fibroblasts.
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Discussion
The results reported concern an ADOA family whose members harbor a new 
OPA1 deletion affecting the GTPase domain. Patients studied developed the 
“classic” ADOA, characterized by childhood onset and slow progression, but a 
depth muscular examination showed subclinical neuromuscular involvement. 
Based on the mitochondrial function analysis we concluded that, in these 
patients, the primary defect is determined by mitochondrial network disruption 
without any appreciable impairment of the oxidative phosphorylation system. 
In order to rule out also latent deficiency in the mitochondrial energy metabolism 
we evaluated ATP synthesis rate and membrane potential in standard growth 
medium and in media determining a more challenging environment in terms 
of  cellular energy demand. 
Regarding ATP synthesis rate we did not find significant differences between 
ADOA and control fibroblasts even though a trend toward increased reduction 
in ADOA samples is observed when fibroblasts are grown in absence of 
glucose or in the medium containing gramicidin. These results indicate that 
under stressing metabolic conditions, it means when high mitochondrial 
efficiency is required, cells containing an altered form of Opa1 are probably 
more vulnerable and this could contribute to explain the particular susceptibility 
of retinal ganglion cells to these genetic defects.
To confirm these results we also evaluated the mitochondrial membrane 
potential in different cellular metabolic conditions. In order to detect also 
latent mitochondrial dysfunction oligomycin has been used during membrane 
potential monitoring. Cells with impaired respiratory chain complexes might 
maintain the electrochemical mitochondrial membrane potential by the 
reversal function of ATP synthase that uses the energy deriving from ATP 
hydrolysis to pump proton into the intermembrane space. In this case, 
blocking the ATP synthase proton channel with oligomycin results in a drop 
of membrane potential as opposed to the expected increase that follows ATP 
synthesis inhibition in healthy mitochondria. Notably and accordingly with our 
results, in both control and patients fibroblasts and myotubes, oligomycin 
treatment resulted in an increase in both TMRM and RH-123 fluorescence, 
indicating that also in presence of this OPA1 mutation membrane potential 
is actively maintained by proton pumping of fully functional respiratory chain 
complexes. 
Unlike reported by Amati-Bonneau et al. [139], which found mtDNA multiple 
deletions in patients with a particular syndromic ADOA phenotype characterized 
by neurological and myophatic signs, in our case the OPA1 mutation does not 
affect mtDNA stability in skeletal muscle. Our results are in disagreement with 
data reported by Zanna et al. [140] showing decreased Complex I-driven ATP 
synthesis in ADOA fibroblasts grown in glucose-free medium. The different 
results obtained studying OPA1 mutations affecting different gene region could 
be due to the possible capability of Opa1 to regulate mitochondrial functions in 
different ways and through interaction with different partners.  
Likely, different OPA1 mutations could differently affect mitochondrial capability 
to produce energy as well as mitochondrial DNA stability: on the basis of this 
hypothesis the possible involvement of tissues different from the optic nerve 
- the classical target of ADOA - could also be explained in ADOA patients. 
Anyway, energy failure  cannot justify the standard and most common ADOA 
phenotype in which retinal ganglion cells are specifically affected. Therefore, it 
could be hypothesized that dysfunctions in Opa1 activity primary act impairing 
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mitochondrial functions that are not directly linked to energy production.   
Indeed, in fibroblasts and myotubes grown in standard medium, this new 
OPA1 mutation induces a collapse in the mitochondrial network providing the
 clear indication that abnormal mitochondrial morphology and distribution could 
have a basic role in ADOA pathogenesis. Interestingly, in myotubes but not 
in fibroblasts, OPA1 mutation leads also to altered mitochondrial distribution: 
the different behavior could be due to relative Opa1 abundance or isoforms 
expression other than to different mitochondrial network regulation in different 
tissues. 
Particularly in optic nerve, altered mitochondria distribution per se could 
be cause of degeneration. The peculiar anatomy of optic nerve requires 
in fact an uneven mitochondrial distribution to match the different energy 
requirements in myelinated and non-myelinated regions. In retinal ganglion 
cells - whose axons form the optic nerve - a non-controlled distribution of even 
well functioning mitochondria could locally lead to insufficient energy supply, 
progressive axonal impairment and apoptotic cell death, while other tissues 
could be not so sensitive to alterations in mitochondrial morphology that are 
not directly linked to energy production defects. 
The fact that mutations in mitofusin 2, another dynamin-related protein, are 
associated to type 2 Charcot-Marie-Tooth syndrome characterized by severe 
axonal peripheral neuropathy, sometimes with subacute optic neuropathy 
confirms that fusion protein activity is fundamental for neuronal cells function 
and could support the hypothesis that mitochondrial morphology could, in 
specific tissues, represent a basic factor for cell physiology.  
Our results indicate that different OPA1 mutations may differently affect the 
protein function and suggest that an accurate exam of ADOA patients might 
reveal subclinical signs in different tissues, helping the understanding of the 
pathogenic mechanism that lead to slow degeneration of optic nerve. 
Apparently, the mutation found in the pedigree analyzed acts primary impairing 
the mitochondrial fusion: the pathogenic mechanism might therefore derive 
from an excessive fission, a lack of complementation between mitochondria or 
from the inhibition of the interaction with motor protein involved in mitochondria 
subcellular distribution. Because of the slow progression that characterizes 
the pathology it can be inferred that the mutation in the OPA1 gene does not 
directly induce cell death but, more probably, a slight, chronic impairment of 
mitochondrial function that, with time, results in the apoptotic commitment of 
retinal ganglion cells.
The parallel study of LHON and ADOA could contribute to better understand 
the physiology of optic nerve, possibly favoring the development of therapeutic 
strategies aimed to mitigate or prevent the effect of these diseases.
results & discussion
63
3 Protection of cells with energy 
deficiency
As shown in the previous paragraphs defects on mitochondrial metabolism 
may have different and deleterious effects on cell physiology. Mitochondrial 
dysfunctions are acquiring great attention from the clinical area because 
of their recognized relevance not only in aging but also in age-related 
pathologies including cancer, cardiovascular diseases, type II diabetes, and 
neurodegenerative disorders [8].
The involvement of mitochondria in such detrimental pathologies enhances 
the necessity of standardization of therapeutic strategies capable of rescuing 
the normal mitochondrial function. However, primarily because of the poor 
knowledge of pathogenic mechanisms underlying these disorders, therapy 
for both primary mitochondrial diseases and late-onset neurodegenerative 
diseases is woefully inadequate. 
Advances in mitochondrial biology and in pharmacology have facilitated the 
design of drugs targeted to mitochondria [62]. Although promising, this is still 
a young field, and there are concerns with “mitochondrial drugs” mainly due 
to our ignorance of the potential long-term toxic effects and our inability to 
regulate drug delivery to target tissues [59]. A promising gene therapy approach 
is the so-called “heteroplasmic shifting”, aimed at lowering the mutant mtDNA 
below the pathogenic threshold by different ingenious techniques, such 
as allotopic expression of the normal gene, but its applicability to humans 
appears remote. 
Experimental evidence suggest that stimulating substrate-level phosphorylation 
to work overtime may be a viable approach to remedy the energy crisis due 
to oxphos impairment in yeast and mammalian cells exposed to ischemia 
and reperfusion [171]. Based on these data and in order to test a potential 
therapeutic approach for mitochondrial pathologies we applied this strategy 
to human cells. We evaluated the effect of exogenous substrates capable of 
stimulating the Krebs cycle flux while at the same time removing the excess of 
reduced pyridine nucleotides (NADH) in oxphos-deficient cells. 
Thus, in order to propose an alternative treatment for energy deficiency-
disorders, we tested the effect of substrates capable to stimulate the 
mitochondrial substrate-level phosphorylation on cell viability and energy 
availability in different experimental cell models, that were grown under 
different metabolic conditions. In fibroblasts, the energy defect was achieved 
by culturing normal cells in presence of oligomycin, a selective inhibitor of the 
ATP synthase complex.
Rescue of energy-deficient resting fibroblasts
We chose resting fibroblasts as experimental model in order to better mimic 
the metabolic state of slowly proliferating post-mitotic tissues, such as brain 
and muscle, that are most severely affected in mitochondrial diseases.  
By maintaining human resting fibroblasts up to 72 h in glucose- and FBS-free 
medium, in which galactose (+ pyruvate) substituted for glucose, anaerobic 
glycolysis was almost abolished [175] but cell viability was fully preserved even 
when cells were exposed to gramicidin and then subjected to a metabolic 
condition of increased energy consumption [176] [fig. 18 a, b]. 
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figure 18 
Substrates rescue cell death in oligomycin-treated fibroblasts.
Cells were incubated in DMEM-enriched medium (a), in the same medium plus 40 ng/ml 
gramicidin (b), or in the same medium plus 40 ng/ml gramicidin and 0.6 nM oligomycin 
(c), as detailed in “Materials and Methods.” Dotted lines (----) denote presence of the 
substrates in the culture medium. 
figure 19 
Microscopical evaluation of fibroblasts viability.
Cells were incubated for 72 hours in DMEM-enriched medium 
(a) or in the same medium plus 40 ng/ml gramicidin (b) or 40 
ng/ml gramicidin + 0.6 nM oligomycin (c), in the absence (a, 
b, c) or in the presence (d, e,f) of the substrates.
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In conditions in which signs of cellular 
distress are absent the addition of 5 mM 
α-ketoglutarate + 5 mM aspartate (from 
now on referred to as “substrates”) to the 
medium does not show detectable effects. 
In contrast, and as expected, adding to the 
medium low concentrations of oligomycin, 
the specific inhibitor of the F0 component 
of ATP synthase complex, caused a sharp 
decrease of viable fibroblasts, about 95% 
of which were dead at 72 hours [fig. 18 c]. 
In the same culture condition the presence 
of substrates clearly show protective effect, 
reducing the mortality to less than 30%.
The protective effect of substrates was 
confirmed by the morphological analysis 
of cells cultured for 72h: resting fibroblasts 
in the galactose medium and forced to 
increased the rate of ATP synthesis by 
exposure to gramicidin (as above) showed 
normal morphology, in accord with the 
viability data [fig. 19 a,b]. However, when 
energy demand was increased and ATP 
synthase was inhibited by oligomycin 
[fig.19 c], the fibroblasts showed marked 
morphological changes, including shrinkage 
and detachment from the dish, typical 
features of cell death. The supplementation 
of the growth medium with 5 mM 
α-ketoglutarate + 5 mM aspartate resulted 
in fibroblasts normal morphology retention 
[fig. 19 d,e,f]. 
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figure 20 
ATP levels in resting oligomycin-treated fibroblasts.
Cells were incubated in DMEM-enriched medium (a), in the same medium plus 40 ng/ml gramicidin (b),  or 
in the same medium plus 40 ng/ml gramicidin and 0.6 nM oligomycin (c). Total ATP levels were assayed every 
day by using a luminescent-based assay (see Materials and Methods).  Dotted lines (----) denote presence 
of the substrates in the medium. At zero time, the ATP content of the fibroblasts was 18.56 +/- 2.50 nmol/
mg protein.
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To verify whether the protective action of substrates was due to their ability 
to supply ATP, we measured the total ATP cellular content and found that the 
addition of α-ketoglutarate and aspartate acts stimulating the mitochondrial 
substrate-level phosphorylation. ATP level was found sufficiently high for cell 
viability [fig. 20].  This was particularly evident in cells challenged by addition of 
both gramicidin, which stimulates the Na+/K+ ATPase, [176] and oligomycin [fig. 
20 c].  Interestingly, the decrease of ATP preceded cell death, thus indicating 
cellular stress even when cell count and morphology were still normal [fig. 18 
c and fig. 20 c]. 
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Effect of the substrates on cybrids homoplasmic for 
NARP T8993G and T8993C mutations 
As addition of the substrates to the growing media showed a protective effect in 
fibroblasts with an artificially induced defect of ATP synthase, we investigated 
whether they could also prevent the death of homoplasmic cybrids carrying 
either one of two mtDNA mutations in the ATP 6 gene associated with NARP. 
NARP cybrids were grown in galactose-pyruvate containing medium in order 
to push the oxidative phosphorylation. 
Substantial protection was observed only in the NARP T8993G cybrids [fig. 
21a and b].  Time course showed, independently by substrates presence, 
normal growth of wild type cybrids. Conversely, after 3 days, about 75% of the 
T8993G cybrids survived in substrates-enriched medium whereas only about 
10% survived in the absence of the substrates.  Significantly, the decrease 
in ATP level of the T8993G cybrids paralleled cells death: residual ATP was 
nearly 10% after 3 days in the absence of substrates, whereas it remained 
above 80% when cells were grown in the presence of substrates [Fig. 21c 
and d].  In contrast, the growth curves of wild type and mutant homoplasmic 
NARP T8993C cybrids were similar [Fig. 22a and b], indicating that also in 
a challenging metabolic environment the presence of the T>C point mutation 
does not affect significantly cell viability. Accordingly, the ATP content was also 
similar in wild type and mutant cybrids [Fig. 22c and d]. Thus, both growth 
and ATP content of wild type and NARP T8993C cybrids were unaffected by 
addition of the substrates to the culture medium.
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figure 22 
Viability and ATP content in wild type and homoplasmic T8993C mutant cybrids.
Viability (a,b) and ATP content (c,d) of wild-type (a,c) and homoplasmic T8993C mutant (b,d) cell lines grew in DMEM-enriched medium. The dotted line 
(----) indicates presence of the substrates. At zero time, the ATP content was 8.33 +/- 0.64 mmol/mg protein in wild-type cells 8.25 +/- 1.39 nmol/mg 
protein in homoplasmic mutant cells.
figure 21 
Viability and ATP content in wild type and homoplasmic T8993G mutant cybrids.
Viability (a,b) and ATP content (c,d) in wild type (a,c) and homoplasmic T8993G mutant (b,d) cell lines grew in DMEM-enriched medium. The dotted line 
(----) indicates presence of the substrates. At zero time, the ATP content was 9.70 +/- 0.99 nmol/mg protein in wild-type cells and 8.07 +/- 0.23 nmol/mg 
protein in homoplasmic mutant cells.
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Discussion
This study is based on the notion that cells with dysfunctional oxphos 
and energy deficiency have to maintain themselves on substrate-level 
phosphorylation in order to compensate for the mitochondrial defect. The limit 
of this potential rescue mechanism is that the substrate-level phosphorylation 
cannot supply sufficient ATP when energy demand is high. However it may 
supply a significant contribution to rescue oxphos-dysfunctional cells since 
the only glycolytic flux, if too high, will result in an increased ATP production 
through substrate-level phosphorylation that induces lactic acidosis, further 
impairing cell metabolism. It is thus clear that mitochondrial defects cannot be 
compensated simply potentiating the anaerobic glycolysis.
In Krebs cycle α-ketoglutarate stimulates the substrate-level phosphorylation 
enhancing the production of succinyl-CoA whose conversion in succinate 
results in phosphorylation of a GDP molecule that can, in turn, give an ATP 
molecule thanks to the action of the nucleoside-diphosphate kinase.
The beneficial action of α-ketoglutarate in a context of energy impairment would 
have limited effect. Cells with impaired ATP synthase are indeed characterized 
by an increased mitochondrial membrane potential that induces a reduction 
of the respiratory chain: the expected final result is an increase in the NADH/
NAD+ ratio, which would inhibit the α-ketoglutarate dehydrogenase reaction 
and possibly render the addition of the substrates useless. The presence of 
aspartate would prevent this stimulating the reoxidation of NADH, according 
to the following mechanism:  α-ketoglutarate is imported into the mitochondrial 
matrix in exchange for malate, which derives from reduction of oxalacetate 
through NADH oxidation. Aspartate represents a source of oxalacetate 
and prevents the accumulation of NADH that can be consumed by malate 
dehydrogenase: the final result would be a stimulation of the α-ketoglutarate 
import into the mitochondrial matrix [fig. 23].
Our results show that the presence of these exogenous substrates has 
beneficial effects in cells with energy deficiency deriving from ATP synthase 
impairment.  
We tested the effectiveness of this strategy on resting fibroblasts cultured in 
a glucose-free medium in which energy deficiency was induced by growing 
cells in presence of oligomycin. Once demonstrated that the beneficial effect 
of substrates on cell survival was specifically due to an increased production 
of ATP through an anaerobic pathway, we evaluated the rescuing approach 
also in cybrids homoplasmic for either one of the ATP 6 mutations associated 
with NARP: T8993C and T8993G.
The different effect showed [fig. 21 and 22] by NARP mutations could be 
easily explained by the different impact that T8993C and T8993G mutations 
have on ATP synthase function. A previous paper published by our laboratory 
demonstrate that the T>C mutation causes only a marginal energy deficiency 
but a relatively high increase in ROS production [53], which might damage cells 
structure, induce the mitochondrial transition pore, and lead to apoptosis [177]. 
A similar correlation between severity of the mutation and pathogenic mechanism 
(impaired ATP synthesis vs increased ROS production) has been documented in 
cultured cells harboring mutations in coenzyme Q10-synthesizing enzymes [178]. Unlike 
T>C, T>G mutation acts primary through ATP depletion so that an increased 
substrate-level phosphorylation represents a reliable rescue mechanism for 
cells harboring this genetic variant of ATP 6 gene.
The lack of benefic effects observed in cybrids homoplasmic for the A8344G 
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figure 23 
Metabolic pathway for anaerobic ATP production by the supplemented substrates.
α-ketoglutarate (α-KG) is transferred by the oxoglutarate carrier to the mitochondrial matrix (32), where it enters 
the tricarboxylic acid cycle. Here, it is converted first to succinyl-CoA, then to succinate by the succinyl-CoA 
synthetase (A-SCS), with generation of ATP. Aspartate (Asp) enters the mitochondria  (33), is transaminated 
to oxaloacetate (OAA), which is reduced to malate (reducing equivalents as NADH are removed from the 
matrix and NAD+ is regenerated to support the reaction catalyzed by the α-ketoglutarate dehydrogenase). 
After leaving the mitochondrial matrix, malate contributes to shuttling α-KG into the organelle. IMM = inner 
mitochondrial membrane.
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tRNALys [fig.24] might further confirm that exposure to α-ketoglutarate/
aspartate achieves benefic effects only if the primary defect in cells is 
determined by impairment in energy production. 
The pathogenic mechanism associated to mutations in mitochondrial tRNA 
genes is completely different form that of mutations in structural genes: 
alterations in tRNAs structure will indeed have deleterious effect on the 
entire mitochondrial translational machine leading to a general impairment 
of mitochondrial metabolism whose consequences certainly overcome the 
energy production ability. The short resistance showed by these cells in 
glucose-free medium - 100% mortality was reached in only 24h - is a clear 
index of how detrimental this mutation can be for mitochondrial activity.  
Therefore, our results suggest that patients suffering for some forms of ATP 
synthase deficiency might benefit from dietary or pharmacological treatment 
based on supplementation of α-ketoglutarate and aspartate. 
However, it cannot be ruled out that administration of α-ketoglutarate and 
aspartate would have positive effects also in patients with defects not directly 
affecting the ATP synthase: pyruvate dehydrogenase- and cytochrome c 
oxidase-related Leigh syndrome [58] or defects of complex II [179], resulting in 
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figure 24 
Viability of MERRF cybrid cell lines.
Viability of wild type (a) and homoplasmic A8344G mutant (b) cell lines grew in DMEM-enriched medium. The dotted line (----) indicates presence of the 
substrates.
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energy failure might as well benefit from this kind of treatment. Increasing 
the energy availability to the optic nerve cells could delay or mitigate the 
optic nerve atrophy, therefore the efficacy of substrate-level phosphorylation 
stimulation might also be evaluated in LHON patients, possibly in combination 
with an antioxidant therapy.
mitochondrial disfunction in hereditary optic neuropathies
materials & methods
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 Protection of cells with energy deficiency
Patients
The characterization of the relation between SOD2 genotypes and MnSOD 
activity in control population has been carried out in 24 individuals aged from 
20 to 50 years characterized for all SOD2 allelic combinations: seven alanine 
homozygotes (AA), ten heterozygotes (AV) and seven valine homozygotes 
(VV).
The same analysis, has been carried out also in two different experimental 
groups composed of four controls for each SOD2 genotype and four 3460/
ND1 LHON patients for each SOD2 genotype.
Patients reported in the ADOA chapter have been described in the AIM 
section.
Cells
After the first biochemical characterization of SOD2 genotypes in control 
group we decided to proceed with the same analysis looking for a possible 
relationship between SOD2 genotypes and the biochemical effect of LHON 
primary mutations on oxphos efficiency.
We chose lymphocytes as experimental model for this study. PBMCs (Peripheral 
Blood Mononuclear Cells) were obtained by Ficoll-Hypaque Plus centrifugation 
of EDTA-treated blood, washed twice in PBS (Gibco) and resuspended in 
RPMI 1640 medium supplemented with 10% heat inactivated FBS, 50 IU/ml 
penicillin and 50 mg/ml streptomycin. PBMCs (1×106 cells/ml) were cultured 
in T-75 flasks for 3 h at 37 °C in a humidified incubator. Lymphocytes (non-
adherent cells) were then harvested, pelleted, resuspended (2×106 cells/ml) 
in fresh medium and cultured for 48 h.
Cells resuspended in 50 mM KH2PO4 pH 7.8 containing 0.1% bovine serum 
albumin and the protease inhibitor cocktail were exposed to sonic oscillation 
for 45 s, in 15 s burst, at 4°C. The total superoxide dismutase activity was 
then measured in the supernatant obtained after centrifugation at 100000 g 
for 30 minutes.
For the biochemical characterization of OPA1-mutated fibroblasts cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 4.5 
g/l glucose, 110 mg/l pyruvate and 4 mM glutamine supplemented with 15% 
Fetal Bovine Serum (FBS), 100 units/ml penicillin, 100 μg/ml streptomycin, 
0.25 μg/ml amphotericin B (standard medium) and incubated at 37°C in 5% 
CO2 atmosphere.
Mitochondrial membrane potential was measured in fibroblasts grown in a 
glucose-free medium supplemented by 5 mM galactose, 110 mg/L pyruvate 
and 15 % dyalized FBS. ATP synthesis was measured in fibroblasts grown in 
standard medium, in galactose medium and in galactose medium in presence 
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of 40 ng/ml gramicidin devoid of dyalized FBS for 48h .
We studied the effect of exogenous substrates in human fibroblasts and 
cybrid lines containing mtDNA derived from NARP and MERRF [180] patients, 
as previously described [181]. Control fibroblast cell lines were established 
from normal subjects with informed consent using standard techniques. 
Briefly, skin biopsies were seeded in Dulbecco modified Eagle’s medium 
(DMEM) containing 4.5 g/l glucose, 110 mg/l pyruvate and 4 mM glutamine 
supplemented with 20% fetal bovine serum (FBS), 100 Units/ml penicillin, 100 
μg/ml streptomycin, and 0.25 μg/ml amphotericin B, and were incubated at 37 
°C in the presence of 5% CO2 until fibroblasts grew out of the biopsies. Cell 
lines were then expanded in complete medium supplemented with 15% FBS. 
NARP and MERRF cybrids were grown in DMEM containing 4.5 g/l glucose, 
110 mg/l pyruvate and 4 mM glutamine supplemented with 10% FBS, 100 
Units/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/ml amphotericin B, 
and only for MERRF cybrids 50 μg/ml uridine, incubating the cells at 37 °C in 
the presence of 5% CO2.
Extraction of human platelet-enriched blood fraction 
(HPBF)
Erythrocytes from venous peripheral blood were sedimented for one hour 
at in 5% dextran 250.000, 0.12 M NaCl, 10 mM EDTA pH 7,4. The fraction 
containing leukocytes and platelets was then centrifuged at 5500 rpm for 10 
minutes. The pellet was subjected to hemolysis and centrifuged at 10500 rpm 
for 10 minutes.
Extraction of soluble fraction from HPBF
The pellet obtained was suspended in phosphate buffer (KH2PO4 50 
mM pH 7,8, 0.3% BSA free fatty acid, Sigma proteases inhibitors cocktail), 
homogenated in electric homogenizer and exposed to sonic oscillation for 
5 minutes, in 15 s burst. After sonication samples were centrifuged at 45000 
rpm for 60 minutes and the supernatant collected for measurement of 
superoxide dismutase activity. 
Mitochondria extraction from HPBF
For mitochondria extraction the pellet obtained after hemolysis was 
suspended in HEPES-buffer (210 mM mannitol, 70 mM saccharose, 1 mM 
EGTA, 5 mM HEPES, 0,3% BSA free fatty acid, proteases inhibitors mix pH 7) 
and incubated with digitonin. From permeabilized sample, mitochondria were 
obtained by differential centrifugations. The discarded pellet, containing nuclei 
and membrane fragments, was used for genotypic characterization while the 
mitochondrial fraction (10-20 mg/ml in mitochondria buffer) was conserved at 
-80°C until use.  
All isolation steps were carried out at 4°C.
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Superoxide dismutase activity assay
The activity of both MnSOD and CuZnSOD was measured in sonicated 
control soluble fraction of HPBF and in lymphocytes according to the nitroblue 
tetrazolium-based assay reported by Oberley and Spitz [182] at 560 nm and 
25°C. The MnSOD activity was evaluated in presence of cyanide in order 
to avoid the contribution of CuZnSOD. CuZnSOD activity was obtained 
subtracting the MnSOD activity from the total activity measured in absence 
of cyanide. Since the MnSOD is a mitochondrial enzyme, comparison of 
its activity in control and in patient cells was done following normalization 
with respect to the activity of citrate synthase, which is a general marker for 
mitochondrial volume in cells.
Catalase activity assay
The catalase activity was measured spectrophotometrically at 240 nm 
following the hydrogen peroxide decomposition according to Aebi et al. [183]; 
the cyanide-sensitivity of the enzyme was assessed in the presence of 0.2–
0.4 mM KCN, as suggested by Heck et al. [184].
ATP synthesis
Cellular ATP synthesis rate was measured by the highly sensitive 
luciferin/luciferase chemiluminescent method. In order to permeabilize cells 
and minimize ATP synthesis by biochemical pathways other than oxidative 
phosphorylation, lymphocytes (20×106 cells/ml) were incubated for 3 minutes 
at room temperature with 60 μg/ml digitonin, 2 mM iodoacetamide, and 
the adenylate kinase inhibitor, P1, P5-di(adenosine-5′) pentaphosphate 
penta-sodium salt (25 μM), in 10 mM Tris (pH 7.4), 100 mM KCl, 5 mM 
KH2PO4, 1 mM EGTA (ethylene glycol tetraacetic acid), 3 mM  EDTA 
(ethylenediaminetetraacetic acid) and 2 mM MgCl2. Complex I driven ATP 
synthesis was induced by adding 10 mM glutamate, 10 mM malate, 2 mM 
malonate and 0.5 mM ADP to the sample. Complex II driven ATP synthesis 
was induced by adding 20 mM succinate, 4 μM rotenone and 0.5 mM ADP to 
the sample. 
The reaction was carried out at 30°C and after 3 min it was stopped by the 
addition of 80% DMSO (dimethylsulphoxide). Synthesized ATP extracted from 
the cell suspension was assayed by the luminometric method as previously 
described [185]: as a blank a sample that was not energized with glutamate/
malate or succinate, but containing both 18 μM antimycin A and 2 μM 
oligomycin and 0.5 mM ADP, was used.
ATP synthesis rate in OPA1-mutated fibroblasts was measured in 1-2 x 106 
cells grown in standard and energy-challenging medium as above reported
Western Blot
Mitochondria were lysed in β-Mercaptoetanolo-SDS buffer and boiled for 2 
minutes. Proteins were separated by SDS-PAGE in 8-16% gradient gel and 
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then blotted into a nitrocellulose membrane. The membranes were saturated 
overnight in blocking solution (KH2PO4 1 mM, NaCl 150 mM, NaH2PO4 3 mM 
pH 7,4 containing 0.05% Tween-20, 2% non-fat dry milk and 2% bovine serum 
albumin).
Primary (E1α rabbit polyclonal IgG-SantaCruz, MnSOD sheep polyclonal 
IgG-Calbiochem) and secondary (horse-radish peroxidase conjugated from 
SantaCruz and Calbiochem)  antibodies were diluted in blocking solution and 
incubated for one hour at room temperature. 
Non-bound antibodies were removed by washing in PBS-0.05% Tween-20 
solution. Protein bands were detected by chemiluminescence method (ECL-
GE Healtcare) with the Fluor-S MultImager System (BioRad). Spots were than 
analyzed by densitometry with Quantity One software (BioRad). 
E1α subunit of mitochondrial pyruvate dehydrogenase complex has been 
considered as loading control for normalization of MnSOD monomers quantity 
in order to minimize differences in the extraction procedures. The ratio between 
the amount of MTS (mitochondrial targeting sequence)-MnSOD (26 KDa) 
and MnSOD (23 KDa) was quantified in the soluble fraction obtained from 
sonicated control HPBF by SDS-PAGE (16-19% gradient) and western blot.
Mitochondrial membrane potential measurement 
Fibroblasts were harvested after trypsinization, washed in PBS (1 mM KH2PO4, 
0.15 M NaCl, 3 mM Na2HPO4) and resuspended in 0.25 M Saccharose, 10 
mM Hepes, 100 μM EGTA, 2 mM MgCl2, 4 mM KH2PO4  pH 7.4, in order to 
obtain a protein concentration of about 2-3 mg/ml. For each measurement 
protein estimation with Lowry method was carried out. 
The steady state mitochondrial electrical potential of permeabilized fibroblasts 
was assessed at 25°C by means of the fluorescent cationic dye Rhodamine-
123 (RH-123), which distributes electrophoretically into the mitochondrial 
matrix in response to the electrical potential across the inner mitochondrial 
membrane [186]. 
Briefly, cell suspension were incubated with an ADP regenerating system 
(5 U/ml hexokinase and 10 mM glucose), 33 nM cyclosporine A in order to 
minimize loss of membrane potential through permeability transition pore, 
2 mM malonate, 0.4 mM ADP, 10 mM glutamate/10 mM malate and 50 nM 
Rhodamine-123 [187].
RH-123 fluorescence quenching (λexc = 503 nm; λem = 527 nm) was measured 
at 25°C after permeabilization with 20 μg/ml digitonin (state 3 respiratory 
condition). State 4 and uncoupled respiratory condition were induced by 
adding 0.4 μM oligomycin and 0.2 μM carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP) respectively. 
Fluorescence micrographs (20x) of adherent permeabilized fibroblasts were 
obtained incubating the cells at 37°C for 7 minutes in respiratory buffer (0.25 
M Saccharose, 20 mM Tris, 4 mM MgSO4, 0.5 mM  EDTA, 10 mM KH2PO4 
pH 7.4) containing 20 μg/ml digitonin, 10 mM glutamate, 10 mM malate, 2 
mM malonate, 0.4 mM ADP and 0.2 μM TMRM (tetramethylrodhamine methyl 
ester) in absence (state 3 respiration) and in presence of 0.4 μM oligomycin 
(state 4 respiration).
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Cell survival
Cell survival was assessed after growth in DMEM-enriched medium 
supplemented or not with substrates for 72 h. Cells were washed with PBS, 
trypsinized, collected, and, if necessary, diluted to 1×106 cells/ml. The cells 
were then incubated in air at room temperature with an equal volume of trypan 
blue dye and counted by three independent investigators (mean ± SD). The 
number of viable cells was expressed as percentage of survival relative to the 
number of cells counted at the beginning of the experiment. 
Morphological analysis
Fibroblasts were plated in 60 mm Petri dishes and cultured for 72 h. Petri 
dishes were washed once with PBS and the cells were immediately visualized 
with an inverted microscope (Olympus IX50 equipped with a monochrome 
CCD camera). Multiple high-power (20x) images were acquired, and cells were 
scored as dead if they appeared smaller or shrunken and brighter, indicating 
release from the dishes.
Measurement of ATP content
ATP content was determined by measuring the light emitted during 
the oxidation of D-luciferin catalyzed by luciferase in the presence of ATP [185] 
(ATP bioluminescent assay kit CLS II; Roche, Switzerland). Briefly, 30 μg of 
cell protein were suspended in 100 mM KCl, 10 mM Tris, 5 mM KH2PO4, 1 mM 
EGTA, 3 mM EDTA, 2 mM MgCl2, pH 7.4, and ATP was extracted in DMSO. 
ATP levels were quantified as nmol/mg protein and expressed as percentage 
of cellular ATP content at the beginning of the experiment (t = 0).
Citrate synthase assay
The citrate synthase activity was assayed essentially as described in 
Trounce et al. [188] by incubating samples in 125 mM Tris pH 8 with 0.2% Triton 
X-100, and monitoring the reaction at 30°C by measuring spectrophotometrically 
the rate of free coenzyme A (90 μM) release at 412 nm. 
The citrate synthase activity has been considered as a general marker for 
mitochondrial volume in cells and its value was utilized for normalization of 
other mitochondrial activities.
Protein Content
Sample protein content was assessed spectrophotometrically (λ= 
750 nm) by Lowry’s method [189] in presence of 0.3% (w/v) sodium deoxycholate. 
Bovine serum albumin was used as standard. 
Statistical analysis
All results are expressed as mean +/- standard deviation. Statistical 
significance of differences between sample populations was evaluated using 
one-way ANOVA followed by Bonferroni post hoc test. 
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Abbreviations
ADOA autosomic dominant optic atrophy
ANT adenine nucleotide translocator
ATP, ADP, AMP adenosine-5’-triphosphate, -diphosphate, -monophosphate
BN-PAGE blue native polyacrylamide gel electrophoresis
DCA dichloroacetate 
DMSO dimethyl sulfoxide
DNP 2,4-dinitrophenol
EDTA ethylenediaminetetraacetic acid
EGTA ethylene glycol tetraacetic acid
EMT electron microscopy tomography
ETC electron transport chain
FADH2 flavine adenine dinucleotide, reduced form
FCCP carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
FMN flavin mononucleotide
HPBF human platelet enriched blood fraction
IMM inner mitochondrial membrane
LHON Leber hereditary optic neuropathy
MELAS myopathy, encephalopathy, lactic acidosis and stroke-like 
episodes
MERRF myoclonic epilepsy with ragged red fibers
MIDD maternal inherited deafness and diabetes
MILS maternal inherited Leigh syndrome
mtDNA mitochondrial deoxyribonucleic acid
MTS mitochondrial targeting sequence
nDNA nuclear deoxyribonucleic acid
NADH nicotinamide adenine dinucleotide, reduced form 
NARP neuropathy ataxia and retinitis pigmentosa
NBT nitroblue tetrazolium
OMM outer mitochondrial membrane
PBS phosphate buffered saline
RET reverse electron transfer
RGC retinal ganglion cell
RH-123 rhodamine-123
ROS reactive oxygen species
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SOD superoxide dismutase
SSBP1 single-stranded binding protein1
TMRM tetramethylrodhamine methyl ester
UCP uncoupling protein
VDAC voltage dependent anion channel
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